AI in cancer detection and treatment

Developing StoryLast updated
SUMMARY

Dassault Systèmes is acquiring ArisGlobal for approximately $1.8 billion on July 23, 2026, to enhance AI capabilities in drug development, while Medidata Plus launched to scale AI in clinical trials. As of July 23, 2026, AI tools are showing promise for earlier pancreatic cancer detection, improved pathology slide analysis, and accurate colorectal cancer diagnosis. Key developments include the FDA clearance of Paige Prostate system, the launch of Latent-Y for drug design, and partnerships like Bristol Myers Squibb with Nvidia for an AI data center. Researchers have also developed AI models like REDMOD and AQuA for early cancer detection and error checking in virtual staining, with an AI-discovered drug projected for FDA approval by 2026–2027.

Timeline

Want updates on this thread?

Track this story

July 2026 — 29 developments

  1. AI Advancements in Cancer Care: Major Acquisition, Early Detection Tools, and Clinical Trial Scaling

    Dassault Systèmes is acquiring ArisGlobal for approximately $1.8 billion to enhance AI capabilities in drug development, while Medidata Plus has launched to scale AI in clinical trials. New AI tools are also showing promise for earlier pancreatic cancer detection and improved pathology slide analysis for tumor classification and recurrence risk prediction.

  2. New AI Models for Cancer Detection and Treatment Monitoring Emerge

    A new AI model integrating cfDNA methylation markers with clinical data for accurate colorectal cancer diagnosis and precancerous lesion detection was discussed in a July 2026 ASCO Daily News article. Additionally, a new AI-powered platform combining 3D bioprinting and advanced imaging to monitor cancer treatment response has been described, and the Cancer AI Alliance has launched projects through Johns Hopkins researchers to enhance cancer diagnosis and treatment.

  3. New AI Tools Enhance Cancer Detection, Drug Development, and Pathology Analysis

    Researchers have developed an AI tool, AQuA, capable of detecting errors in AI-generated "virtual staining" of tissue samples. New methodologies enable AI models to adapt to out-of-domain scenarios in bioactivity prediction, and an AI model, REDMOD, can detect pancreatic cancer on CT scans up to three years before clinical diagnosis. Telefónica and Harrison.ai have partnered to offer an AI solution in Spain that analyzes chest X-rays for lung cancer screening.

  4. New AI Tools Accelerate Cancer Drug Design and Treatment Research

    Latent Labs has launched Latent-Y, a free AI-driven drug design tool that identifies suitable targets and delivers lab-ready sequences with high efficiency. UCLA Health researchers have developed a platform combining 3D bioprinting, advanced imaging, and AI to rapidly monitor cancer's response to treatment. A study presented at the 2026 ASCO Breakthrough Meeting suggests patients prefer AI-simplified clinical trial information.

  5. AI Drug Approvals Projected, Major Acquisitions and Development Platforms Advance Cancer Care

    Bristol Myers Squibb is building a large AI data center with Nvidia, and the first FDA approval of an AI-discovered drug is projected for 2026–2027. Tempus AI is acquiring Personalis for $1.5 billion to expand AI-driven diagnostics, while Recursion uses its AI platform to develop treatments for aggressive cancers and rare diseases more efficiently. New AI models can translate a tumor's genetic profile into predictions about its response to treatment.

  6. FDA Clears AI for Prostate Cancer Detection; New Models Predict Pancreatic Cancer and Treatment Response

    The FDA has cleared the Paige Prostate system, a fully autonomous AI for prostate cancer detection. Researchers have developed AI models capable of detecting pancreatic cancer on CT scans up to three years before diagnosis and predicting treatment response based on a tumor's genetic profile. AI is also being used to accelerate cancer drug research and streamline clinical trial processes.

  7. AI Integrated into NHS Labs for Prostate Cancer Diagnosis; CellCarta Launches AI Consortium; Chai Discovery Raises $400M

    AI has been safely and effectively integrated into NHS histopathology labs for prostate cancer diagnosis, aiding in detection and grading. Separately, CellCarta launched a Global Digital Pathology and AI Consortium to accelerate biomarker discovery and clinical trial execution. Chai Discovery also raised $400 million to advance its AI-designed drug discovery efforts.

  8. AI Partnerships Accelerate Cancer Drug Discovery and Treatment Prediction

    SK Telecom and SK Biopharmaceuticals have used AI to reduce cancer drug discovery time by 60%, from one to two years to approximately five months. Insilico Medicine and Bora Pharmaceuticals formed an alliance to advance AI-driven drug innovation, potentially valued over $2.5 billion. Ardigen and VERAXA Biotech are partnering to develop AI tools for cancer target selection, aiming to bring precision oncology therapies to patients faster. Stanford Medicine researchers developed an AI platform, CANVAS, that predicts immunotherapy resistance across nine cancer types.

  9. ASCO Partners with Ryght AI to Accelerate Oncology Trial Site Selection

    The American Society of Clinical Oncology (ASCO) has partnered with Ryght AI to utilize its 'AI Site Twin' platform. This collaboration aims to analyze clinical research site data and accelerate oncology trial site selection, while also addressing clinical trial enrollment delays by identifying eligible patients and optimizing site selection.

  10. New AI Tools Advance Lung Cancer Prediction and Immunotherapy Response

    Researchers have developed an AI-powered method using fluorescence lifetime imaging microscopy (FLIM) to predict lung cancer by analyzing DNA genetic changes, potentially reducing diagnosis time to minutes. Separately, an AI model named COMPASS can predict patient response to cancer immunotherapy drugs with higher accuracy, and generative AI is being explored to personalize adaptive cancer treatments.

  11. AI Improves Lung Cancer Diagnosis Rates, Enhancing Early Detection

    UCLA Health is leveraging AI-powered platforms to enhance lung cancer diagnosis, with Sarasota Memorial reporting 75% of cases diagnosed at Stage I or II in 2025. This advancement significantly improves early detection rates, crucial for effective treatment and patient survival.

  12. Israel Launches AI Consortium for Drug Discovery; Mayo Clinic AI Detects Pancreatic Cancer Early

    Israel has launched the Israel BioToken Factory Initiative, a national AI R&D consortium with a 70 million shekel investment to accelerate drug discovery and personalized medicine, with initial applications in oncology. Separately, a Mayo Clinic AI model, REDMOD, can detect signs of pancreatic cancer on routine CT scans up to three years before clinical diagnosis.

  13. AI Blood Test Shows 99% Accuracy for Womb Cancer; Other AI Tools Detect Cancers Years Earlier

    The NHS is trialing a new AI-powered blood test for womb cancer with a reported 99% accuracy rate. AI models are also showing promise in detecting pancreatic cancer up to three years before diagnosis and flagging early signs of breast cancer up to six years prior. Additionally, an AI-guided outreach program has demonstrated an increase in cancer screening rates and a reduction in mortality.

  14. IIIT-Delhi Researchers Use AI and Genomics for Early Cancer Detection

    Researchers at the Indraprastha Institute of Information Technology Delhi are using AI and genomics to detect early cancer signals in blood and tissue, aiming to create affordable screening tools.

  16. New AI Platforms and Drug Development Principles Emerge in Cancer Research

    Stanford Medicine researchers have developed an AI platform named CANVAS that analyzes pathology slides to infer cellular neighborhoods and predict immunotherapy resistance. The FDA and EMA have finalized joint guiding principles for the use of AI in drug development, establishing a framework for clinical submissions. Insilico Medicine's AI-originated therapeutic, Rentosertib, has advanced to Phase 3 clinical trials.

  17. New AI Legislation for Pediatric Cancer, Blood Test for Womb Cancer Trials

    The bipartisan Accelerating Innovation (AI) for Kids Act has been introduced to leverage AI for improving pediatric cancer research and treatment options. Separately, an AI-powered blood test is showing high accuracy in detecting womb cancer, potentially sparing women painful examinations. Discussions at ASCO 2026 emphasized the need to scale AI in cancer care, focusing on coordinated reliability and patient-centered implementation.

  18. New AI Tools Aid Cancer Detection During Surgery and Predict Recurrence

    Researchers are utilizing a light-based imaging technique combined with machine learning for real-time detection of head and neck cancers during surgery. Additionally, an AI system can analyze pathology slides to predict meningioma recurrence, and AI-designed antibodies have entered Phase 1 clinical trials for inflammatory bowel disease.

  19. New AI Platforms Launched to Combat Cancer Drug Resistance and Predict Immunotherapy Response

    Oscotec unveiled ACART, an AI-based platform designed to track how cancer cells acquire resistance to drugs and identify the causes, aiming to address tumor heterogeneity and predict drug resistance. Separately, the AI tool COMPASS has been developed to predict which patients are likely to respond to cancer immunotherapy drugs.

  20. AI Platform Monitors Tumor Response; Researchers Discover New Cancer Evasion Mechanism

    A new platform integrates 3D bioprinting, advanced imaging, and AI to monitor tumor response to treatment, enabling personalized treatment decisions by testing drugs on a patient's own tumor cells. VCU Massey Cancer Center researchers have identified a novel mechanism that cancer cells use to evade the immune system, offering a new target for cancer therapies.

  21. AI advances in cancer treatment: $10M grant for VCU Massey, improved screenings

    VCU Massey Cancer Center received a $10 million grant to develop an AI-powered platform for accelerating cancer therapy identification and guiding personalized treatment decisions. Additionally, an AI-guided outreach program has successfully increased cancer screenings and reduced mortality.

  22. New AI tools enhance cancer detection and clinical trial simulation

    Researchers have developed an AI system that simulates clinical trials to make them faster and more precise. Additionally, an AI platform called CANVAS can predict cellular neighborhoods within tumors from pathology slides, offering insights into cancer's structure and potential weaknesses. AI-assisted colonoscopies have also shown to significantly increase the detection of precancerous lesions.

  23. AI Blood Tests Launched, Clinical Trials Initiated for Cancer Detection and Treatment

    Reliance Industries subsidiary Strand Life Sciences and Caris Life Sciences have launched new AI-powered blood tests for early cancer detection. Insilico Medicine has initiated a Phase III clinical trial for Rentosertib, an AI-discovered drug for idiopathic pulmonary fibrosis. Additionally, new AI platforms and tools are being developed to accelerate therapy discovery, improve clinical trial design, and predict treatment responses.

  24. AI Blood Tests Show Promise for Cancer Detection; FDA Accepts AI Tool for Liver Injury Prediction

    Researchers have developed an AI blood test showing promise for detecting brain and lung cancers, and another AI test that predicts breast cancer recurrence risk from pathology slides. Additionally, an AI-driven tool for predicting Drug-Induced Liver Injury (DILI) has been accepted into the FDA's Drug Development Tool Qualification Program, marking a significant regulatory milestone for AI in drug safety.

  25. Absentia Labs' AI liver model accepted into FDA's Drug Development Tool Qualification Program

    Absentia Labs' AI-Driven Digital Liver Model for predicting Drug-Induced Liver Injury (DILI) has been accepted into the FDA's Drug Development Tool Qualification Program. This marks a milestone for AI in drug development safety assessment.

  26. New AI blood test detects liver cancer; AI speeds up clinical trial design

    A Johns Hopkins study reveals an AI blood test capable of detecting liver cancer with over 80% accuracy, even in early stages. Additionally, AI systems are reportedly reducing clinical trial construction time by up to 75%, accelerating cancer research and development.

  27. AI advancements in cancer detection and treatment include new recurrence prediction test and early detection urine sensor.

    NYU researchers have developed a multimodal AI test to predict breast cancer recurrence by analyzing pathology slides and clinical data. Separately, MIT and Microsoft researchers created an AI model that designs peptides for molecular sensors in a urine test for early cancer detection. GT Biopharma is integrating AI tools to accelerate the creation of new tumor-targeting therapies, aiming for multiple new development candidates in 2027.

  28. New AI Model COMPASS Enhances Cancer Immunotherapy Response Prediction

    Researchers have developed a new AI model named COMPASS that improves the prediction of cancer patients' response to immune checkpoint inhibitor therapies. This advancement, along with generative AI platforms optimizing drug discovery, is significantly shortening the timeline from target identification to clinical trials.

  29. AI-Designed Cancer Drugs Nearing Approval, Over 173 Programs in Clinical Development

    The first AI-designed cancer drug is anticipated for approval between 2026 and 2027, with over 173 AI-originated drug programs currently in clinical development. GT Biopharma is enhancing its drug discovery processes with AI, expecting multiple new candidates to enter pre-IND development in 2027.

June 2026 — 40 developments

  1. China to Launch First AI-Powered Personalized Cancer Vaccine Production Line

    China is set to launch its first AI-powered personalized cancer vaccine production line in Beijing, aiming to design patient-specific treatments within 24 hours. The facility, developed by Likang Life Sciences, is expected to begin operations by October. Additionally, the Mayo Clinic has developed an AI model that can detect pancreatic cancer on routine CT scans up to three years before clinical diagnosis.

  2. AI Advances in Cancer Detection and Treatment: New Targets, Platforms, and Diagnostics

    An AI framework has been developed to identify new targets for CAR T cell therapy, demonstrating robust tumor-killing activity in preclinical models. A new AI platform named "GENAI ME" has been launched to accelerate personalized cancer treatments for Korean patients. The world's largest database of chemical reactions has been launched to aid AI-driven drug discovery. AI tools are enhancing diagnostic accuracy and efficiency in pathology for breast cancer, and a portable, AI-assisted endomicroscope has been developed for early epithelial cancer detection.

  4. AI Advancements in Cancer Detection and Drug Development Reported

    Aidoc received FDA Breakthrough Device Designation for its AI tool First Read, which analyzes chest radiographs to generate preliminary radiology report text. The University of Utah is developing quantum-inspired AI to personalize cancer treatment by analyzing vast molecular data. Israeli-founded AI biotech Immunai is collaborating with Boehringer Ingelheim to utilize its single-cell AI platform for identifying T-cell targets for new drugs. The market for in-silico and AI-based drug discovery technologies is experiencing significant growth, with oncology being a leading segment.

  5. AI Methods Advance Cancer Drug Design and Discovery with New Platforms and Trial Results

    Researchers at Dana-Farber Cancer Institute have developed an AI method called NISE to design proteins that can act as carriers or protective shells for cancer drugs, aiming to make them safer and more precise. Purdue University has created an automated platform integrating synthesis, testing, and mass spectrometry to rapidly identify potential cancer treatments. Insilico Medicine reported promising Phase 2a trial results for Rentosertib, an AI-identified and designed drug candidate.

  6. AI advances in cancer detection include avoiding chemotherapy, faster MRI scans, and improved pathology diagnostics

    AI analysis of immune cells near tumors can help determine which breast cancer patients can safely avoid chemotherapy. A new AI-powered method named ELITE has been developed to make cancer MRI scans faster and more accurate. Digital Pathology combined with AI is revolutionizing diagnostic accuracy and efficiency by enabling automated image analysis and predictive analytics.

  7. AI Drug Candidate Selected for Korean National Program; UCLA Develops New Therapy Identification Platform

    Galux's AI-designed immuno-oncology drug candidate, PD-1/IL-18v, has been selected for a national development program in Korea. UCLA Health has also developed a new AI-powered platform combining 3D bioprinting and imaging to accelerate the identification of cancer therapies.

  8. AI advancements in digital pathology and clinical trials accelerate cancer treatment development

    Researchers have developed TRUECAM, an AI framework designed to increase trustworthiness in digital pathology by quantifying uncertainty and identifying out-of-scope inputs. The FDA is piloting the use of AI for real-time clinical trials to accelerate drug development, with initial proof-of-concept trials underway. BostonGene is also presenting AI innovations aimed at improving the accuracy of predicting patient responses and toxicity risks to speed up drug development.

  9. AI Drug Candidate Receives FDA Clearance; New Tools Predict Cancer Metastasis

    An AI-designed drug candidate, AH-008, has received FDA Investigational New Drug clearance, significantly shortening its development timeline. Additionally, an AI tool named MangroveGS can predict cancer metastasis with approximately 80% accuracy, and researchers have developed a platform combining 3D bioprinting, imaging, and AI to accelerate the identification of cancer therapies.

  10. AI-Driven Cancer Drug Trials Begin, New Pathology Model Developed

    The first AI-driven cancer drug clinical trial is anticipated in early 2026, with Google DeepMind having 17 ongoing projects. A new AI-based pathology model, Prov-GigaPath, has been developed, demonstrating superior performance in diagnosing cancer cells. Additionally, a collaboration aims to predict clinical trial outcomes for multiple cancer indications using AI.

  13. New AI Models Developed for Cancer Treatment Response and Metastasis Prediction

    Researchers have developed an AI model named ARTEMIS that measures entire tumor volumes, demonstrating superior performance over human assessments and standard RECIST criteria in evaluating treatment response for pleural mesothelioma. Additionally, an AI model, MangroveGS, has been developed capable of predicting cancer metastasis with approximately 80% accuracy, potentially aiding clinicians in making informed treatment decisions.

  14. AI advances in cancer detection and drug discovery include real-time brain tumor diagnosis and FDA pilot program

    A new AI-assisted imaging technique shows potential for real-time brain tumor diagnosis during surgery. An integrated DESI-MS platform has been developed to significantly accelerate cancer drug discovery by enabling rapid screening and analysis of tens of thousands of molecules. The US FDA has extended the comment period for its real-time clinical trial pilot program, exploring AI's role in accelerating early-phase drug research.

  15. AI Advancements Accelerate Cancer Drug Development, Detection, and Surgical Planning

    New AI platforms are being developed to automate laboratory operations, accelerate case review, and integrate with clinical trial workflows, aiming to reduce the burden on pathologists. AI is also being used to create 'digital twins' of patient anatomy for personalized surgical planning and navigation, and to classify brain tumors with unprecedented accuracy.

  16. AI advances in cancer detection, treatment planning, and clinical trial recruitment reported

    AI-based computer-assisted detection systems can identify early warning signs of breast cancer up to six years before diagnosis. Researchers have developed PATH-zle, an AI technology that reconstructs fragmented tumor samples into complete images with an 83% success rate. Northwestern Medicine is collaborating with Vizlitics to implement AI tools for cancer clinical trial recruitment.

  17. AI Advances in Cancer Detection and Drug Discovery Reported

    AI-powered X-ray tools are being rolled out across the UK's National Health Service (NHS) to assist radiologists in detecting lung cancer earlier. An AI imaging technique has also demonstrated accuracy in detecting endometrial cancer, offering a noninvasive alternative to traditional biopsies. Furthermore, LG Chem has partnered with LabGenius Therapeutics to develop next-generation antibody therapies for cancer using AI.

  18. AI Advances: New Pathology Imaging System and Cancer Drug Trial Clearance

    Researchers at HKUST have developed Glanzir®, the world's first AI-enabled, slide-free pathology imaging system. Concurrently, Insilico Medicine's AI-designed drug candidate, INS018-022, has received FDA clearance to enter Phase 2 trials for pancreatic cancer. These advancements are being highlighted at the 22nd European Congress on Digital Pathology (ECDP 2026).

  19. LG Chem, NIMS, IISc, and Coreline Soft Announce New AI Partnerships for Cancer Research

    LG Chem has partnered with UK-based LabGenius Therapeutics to accelerate AI-driven cancer drug discovery using LabGenius's EVA platform. The Nizam's Institute of Medical Sciences and the Indian Institute of Science have launched a joint research program to develop AI models for early disease detection and personalized treatment. Coreline Soft and Mint Medical are enhancing AI-enabled lung cancer screening through a partnership integrating Coreline Soft's AVIEW platform.

  20. AI Systems Match Physician Capabilities; UConn Gets Funding for Lung Cancer Detection AI

    Two AI systems, MIRA and AMIE, have shown diagnostic and treatment planning capabilities comparable or superior to physicians in virtual trials. The University of Connecticut (UConn) received NIH funding to develop a smartphone-based AI platform for early lung cancer detection, aiming for faster, more affordable, and accessible screening.

  21. FDA Extends AI Clinical Trial Pilot Comment Period; London Launches AI Healthcare Sandbox

    The U.S. FDA has extended the comment period for its real-time clinical trial pilot program, aiming to enhance trial efficiency with AI. In parallel, London launched a regulatory sandbox to accelerate the safe adoption of AI in healthcare, while Asimov partnered with McGill University and Axcelead DDP joined Lilly's TuneLab for AI-driven drug discovery.

  22. AI advancements accelerate cancer drug discovery and diagnosis through new tools and collaborations

    Insilico Medicine has completed first-in-human dosing for ISM8969, an AI-driven NLRP3 inhibitor, as part of its collaboration with Hygtia Therapeutics. LG Chem is intensifying its AI-driven drug development efforts by partnering with AbTherx Therapeutics and LabGenius Therapeutics to discover next-generation cancer drug candidates using generative AI. Additionally, new AI tools like AI-GUR and MangroveGS have been developed to predict prostate cancer reclassification risk and cancer spread, respectively.

  23. G7 Summit Endorses AI in Cancer Detection and Treatment, Emphasizes AI Fluency in Clinical Development

    The G7 Évian Summit has endorsed AI and digital technologies for cancer detection and treatment, signaling a mainstreaming of AI in foreign policy agendas related to healthcare. There is also a growing emphasis on AI fluency within clinical development, with organizations rebuilding core processes and workforces around AI as a default approach for drug development.

  24. UK Government Invests in AI for Cancer Diagnosis; JW Pharma to Lead AI Drug Development Initiative

    The UK government is investing in AI technologies to modernize the NHS and speed up cancer diagnoses, with AI tools set to act as a 'second pair of eyes' for radiologists. JW Pharmaceutical has been selected to lead a government initiative for structure-based new drug development using generative AI. Proscia launched the fifth generation of its Concentriq platform, integrating advanced AI for drug discovery and development. Cleveland Clinic Abu Dhabi launched 'Aila,' an AI platform designed to support real-time clinical decision-making and accelerate medical research.

  25. AI-Guided Treatment to be Investigated in Intensive Care Trial in New Zealand and Australia

    The REVOLUTION trial, a major clinical trial in New Zealand and Australia, will investigate if AI-guided treatment can improve survival rates in intensive care units. This trial explores the application of AI in critical care settings.

  26. AI Accelerates Cancer Drug Discovery and Clinical Trials with New Platforms and Pacts

    Purdue University has developed a new technology platform to accelerate cancer drug discovery by integrating chemical synthesis, biological testing, and mass spectrometry. Seen & Heard Health launched its proprietary AI recruitment platform for clinical trials to address participant shortages. The G7 leaders pledged to foster innovative international research programs and improve cooperation on clinical trials.

  27. AI systems advance cancer diagnosis with new tools for brain and prostate tumors

    The UAE has introduced an AI-supported pathology system to expedite prostate cancer diagnosis, while the 'Hetairos' AI system can classify over 100 brain tumor subtypes from pathology slides. Additionally, Ibex Medical Analytics received FDA clearance for 'Prostate Detect,' an AI tool for highlighting prostate cancer on biopsy slides.

  28. AI Platforms Awarded, Achieve High Accuracy, and Speed Up Cancer Diagnosis

    Evaxion A/S received the 2026 Prix Galien UK Award for its AI-Immunology™ platform, while the PRET AI pathology system demonstrated 100% accuracy in identifying 18 cancer types. Additionally, the Mirai AI model has significantly reduced breast cancer diagnostic timelines from weeks to approximately one hour, and Eli Lilly invested in Abridge AI to enhance clinical trial recruitment.

  29. FDA Explores AI for Real-Time Clinical Trials; NIH Funds AI Cancer Research

    The FDA is exploring the use of AI to potentially shorten drug development timelines through real-time clinical trials, while the NIH is actively funding and conducting research on AI applications in cancer detection, diagnosis, and treatment. Researchers are also developing AI models that can predict molecular evolution, with one model reportedly over 10,000 times faster than conventional simulations.

  30. AI Shows Promise in Early Breast Cancer Detection and Drug Safety Testing

    Research published on June 9, 2026, indicates AI systems can predict breast cancer up to six years before diagnosis from mammograms, potentially reducing interval cancers. The UK's MHRA is launching a regulatory sandbox to test AI for improving medicines safety and predicting side effects, aiming to accelerate drug development. Additionally, new AI applications are being developed for bladder cancer testing, digital pathology labs, and predicting tumor recurrence.

  31. AI advances in cancer detection and treatment include new genomic insights, antibody design, and faster diagnostics.

    Tempus AI launched 'Preview,' an AI application delivering preliminary genomic insights within 24 hours of tissue receipt to aid precision oncology. Chai Discovery's AI for antibody design has doubled success rates, leading to a Pfizer licensing agreement. Additionally, an AI tool can now reduce breast cancer diagnostic evaluation times from weeks to an hour, and M42's National Reference Laboratory is introducing AI-powered prostate cancer diagnostics in the UAE.

  32. AI Advances in Cancer Detection and Drug Discovery Highlighted by New Trials and Funding

    UCL researchers are leading an international trial on AI for prostate cancer detection using MRI scans. Mayo Clinic researchers have developed an AI model capable of detecting pancreatic cancer on routine CT scans up to three years before clinical diagnosis. Several companies, including Insilico Medicine, Chem-Discovery, and Oncotelic Therapeutics, are advancing AI-driven drug discovery platforms, with Isomorphic Labs planning to enter Phase 1 clinical trials for an AI-designed cancer drug by the end of 2026.

  34. AI Collaborations Advance Cancer Pathology and Tumor Classification

    Leica Biosystems, Indica Labs, and Lunit have partnered to create AI-powered image analysis algorithms for biomarkers like PD-L1, aiming to enhance cancer research. Mayo Clinic researchers developed deep learning models that can analyze pathology slides to classify brain tumors and predict recurrence risk. Additionally, Slideflow Labs, a cancer pathology AI company, secured $575,000 to develop AI infrastructure for improving cancer prognosis and recurrence prediction.

  36. AI Advances in Drug Design and Pathology Mapping Accelerate Cancer Research

    Researchers have developed AI frameworks capable of designing novel chemical entities with specific biological effects without a predefined target, and have created a model that generates detailed immune maps from standard pathology slides. These advancements aim to accelerate drug discovery and make cancer research more cost-effective and scalable.

  37. AI Blood Test Predicts Lung Cancer Risk Years in Advance; Market to Double by 2030

    A new AI-powered blood test can predict lung cancer risk over five years before diagnosis by identifying a signature of 14 proteins. The global AI in cancer diagnostics market is projected to grow from $0.96 billion in 2026 to $1.97 billion by 2030.

  38. Tempus AI Launches Digital Pathology Consortium; AI Detects Pancreatic Cancer Years Early

    Tempus AI has launched a digital pathology open-source consortium with Yale New Haven Hospital and Memorial Sloan Kettering Cancer Center to develop a standardized platform leveraging AI for cancer detection and molecular profiling. Separately, Mayo Clinic research indicates an AI model can detect pancreatic cancer on CT scans up to three years before clinical diagnosis.

  39. AI Advances in Cancer Detection, Drug Development, and Clinical Trials Reported

    Researchers have identified a new druggable site in a cancer-related protein using AI, and are developing domain-specific Large Language Models for oncology. An AI tool can now predict metastasis and colon cancer recurrence with nearly 80% accuracy, while AI is also being integrated with augmented reality for prostate biopsies. Additionally, AI is being used to analyze mammograms for high-risk women and to design drug molecules from scratch.

  40. South Korea Develops AI Model to Predict Drug Efficacy

    South Korea's National Cancer Center is developing an AI 'biological world model' to predict the efficacy of new drug candidates. This AI system aims to improve success rates and shorten development timelines by acting as a 'virtual clinical trial site'. The development is part of a global trend of AI transforming drug discovery.

May 2026 — 31 developments

  1. Tempus AI Launches Next-Generation Lens Platform to Accelerate Drug Development

    Tempus AI has launched the next generation of its Lens platform, integrating multimodal data and AI tooling to accelerate drug development and research. The platform is already utilized by 19 of the top 20 biopharma companies.

  2. Tempus AI Gains FDA Approval for Oncology Platform; Nucs AI Partners on Predictive Models

    Tempus AI received FDA approval for its xT CDx next-generation sequencing platform for tumor-only indications. Nucs AI is collaborating with AstraZeneca to develop AI-driven response prediction models for therapeutic radioconjugates. These advancements highlight AI's growing role in precision oncology and drug development.

  3. FDA Proposes Pilot for AI Tools in Clinical Trials Amid Trust Concerns

    The FDA is advancing AI oversight in clinical development with a proposed pilot to assess AI-enabled tools for improving decision-making in early-phase clinical trials. Experts cite trust and regulatory uncertainty as major barriers to AI adoption in clinical trials, despite its potential for data cleaning, analysis, and patient sourcing.

  4. Myriad Genetics Launches AI-Enhanced Prostate Cancer Test; New AI Sensors for Early Detection

    Myriad Genetics has launched the Prolaris + AI Test, combining genomics with AI for prostate cancer detection. Additionally, a novel AI-generated sensor approach using peptides shows potential for early cancer detection through at-home urine tests. AI models are also being developed to identify cancer survivors at risk for emergency visits, shifting survivorship care towards a proactive approach.

  5. Tempus AI Launches Prostate Cancer Test; Collaboration Advances Digital Pathology

    Tempus AI, Inc. has launched its ArteraAI Prostate Test for metastatic patients and will present abstracts on AI-driven oncology research at the 2026 American Society of Clinical Oncology Annual Meeting. Additionally, Leica Biosystems, Indica Labs, and Lunit have integrated AI-driven biomarker scoring into digital pathology workflows to accelerate precision oncology research.

  6. AI Advances in Cancer Care: New Drug Trials, Diagnostics, and Funding Announced

    Binghamton University researchers developed a method to reduce AI 'hallucinations,' enhancing reliability for medical diagnoses. Quotient Sciences began the first clinical study of an AI-designed drug formulation. DELFI Diagnostics' AI-powered blood cancer tests are now available nationwide. Triomics raised $22 million to scale its oncology AI platform.

  7. AI detects cancer odors, speeds drug development, and predicts pancreatic cancer early

    SpotitEarly unveiled LUCID 2.0, an AI platform integrating canines to detect cancer odor signatures in breath samples with 94% sensitivity. Johnson & Johnson reported using AI to halve the time for generating drug development leads and significantly reduce clinical trial report preparation. Mayo Clinic research shows an AI model can detect pancreatic cancer up to three years before clinical diagnosis.

  8. AI in Cancer Care: New drug formulation study, brain cancer detection, and faster diagnostics

    Quotient Sciences has initiated the first clinical study of an AI-designed drug formulation, validating AI's role in accelerating drug development. An AI-powered liquid biopsy shows promise in detecting brain cancer with approximately 75% accuracy, and AI is being integrated into mammogram reading to improve cancer detection rates. Finnish researchers are also employing AI to speed up the analysis of colorectal cancer tissue samples.

  9. AI Identifies Novel Anti-Cancer Compound, Advances Drug Development and Diagnostics

    An AI platform has identified Compound 8a, a novel compound demonstrating significant anti-cancer activity against colorectal cancer by targeting glycoprotein 130 (gp130). Massive Bio is set to launch its AI operating system designed to enhance oncology access and streamline clinical trial participation at the 2024 ASCO Annual Meeting. Quotient Sciences has commenced a Phase I clinical study for an oral drug formulation that was designed using artificial intelligence. Foundation Medicine is introducing new advanced digital solutions that utilize AI to expedite cancer treatment decisions. Researchers in Finland are employing AI to accelerate the analysis of colorectal cancer samples. The U.S. Food and Drug Administration (FDA) is extending the public comment period for its pilot program focused on AI-enabled optimization of early-phase clinical trials.

  10. FDA Extends Comment Period for AI Clinical Trials Pilot; New AI Cancer Detection Methods Emerge

    The FDA has extended the comment period for its AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program until June 29, 2026. Researchers are developing AI models for early cancer detection via urine tests and for monitoring cardiotoxicity in breast cancer patients undergoing treatment.

  11. FDA Seeks Public Comment on AI Pilot Program for Clinical Trials; Biomunex Announces AI Collaborations

    The U.S. Food and Drug Administration (FDA) is seeking public comment on a pilot program to test AI in early-stage clinical trials, aiming to improve patient recruitment, optimize dose escalation, and enhance safety monitoring. Biomunex is also announcing strategic AI collaborations to accelerate the discovery and development of its cancer immunotherapies.

  12. AI accelerates oncology drug development with new asset progressing to IND-enabling research

    XtalPi Holdings has made significant progress in its AI drug discovery collaboration, with a multi-cancer-targeted asset moving to the IND-enabling research phase. The global digital pathology market is growing due to AI-powered diagnostics, and AI is reportedly enhancing clinical trial efficiency, leading to shorter timelines.

  13. Tempus AI upgrades platform with generative AI; Advocate Health partners on AI for clinical trial screening

    Tempus AI has upgraded its platform with generative AI to provide healthcare providers with insights into cancer treatment options and clinical trial information. Advocate Health is partnering with an AI platform to automatically screen patients for cancer clinical trial eligibility directly from their electronic health records, significantly reducing assessment time.

  14. AI Advances in Cancer Research: New Drug Development, Discovery Platforms, and ASCO Presentations

    South Korean scientists have launched a project to develop next-generation blood cancer treatments using AI, funded by the Ministry of Health and Welfare. Chinese researchers developed an AI platform, GalaxyVS, capable of screening vast chemical compound libraries in seconds to accelerate drug discovery for various diseases. Mayo Clinic researchers will present studies on AI-enabled analysis of the tumor microenvironment in colon cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting.

  15. PREMIA and Lind Launch Lind Asia to Revolutionize Clinical Trial Enrollment with AI

    PREMIA and Lind have formed Lind Asia, a joint venture that combines regional clinical-genomic infrastructure with an AI-powered screening platform to revolutionize clinical trial enrollment in the Asia-Pacific region. This initiative is part of the broader acceleration of cancer research and treatment through AI.

  17. Myriad Genetics, Grundium, and Pictor Labs Launch New AI Tools for Cancer Detection and Pathology

    Myriad Genetics has launched the Prolaris + AI Test, combining genomics with AI-powered digital pathology for enhanced prostate cancer assessment. Grundium's acquisition of Visiopharm integrates AI-driven precision pathology software with advanced imaging capabilities, and Pictor Labs launched an NVIDIA-powered on-premises AI system for virtual staining in pathology.

  18. AI Advances: New Tools for Drug Discovery, Cancer Treatment, and FDA Oversight

    Owkin launched an "agentic AI Scientist" to accelerate drug discovery, while Biomunex partnered with AI firms to boost cancer immunotherapy discovery. Research presented at ESMO Breast Cancer 2026 demonstrated AI's improved prediction of distant recurrence in early breast cancer. The FDA also initiated a pilot program to assess AI-generated evidence in drug submissions.

  19. FDA Launches AI-Driven Clinical Trial Pilot; Generative AI Explored for Adaptive Cancer Treatments

    The FDA has launched its first real-time, AI-driven clinical trial pilot program in May 2026, aiming to reduce drug approval times by 20-40% through continuous cloud monitoring. Generative AI is also being explored to support adaptive treatments and counter therapeutic resistance by learning from continuously updated patient data.

  20. New AI Tools Enhance Cancer Treatment Prediction, Diagnostics, and Risk Assessment

    Researchers at UC San Diego developed MutationProjector, an AI model that predicts cancer treatment response based on genetic landscape. UCLA created AQuA to detect errors in AI-generated virtual tissue staining, enhancing digital pathology accuracy. Tempus launched the ArteraAI Prostate Test, an AI tool for personalized prostate cancer mortality risk assessment.

  21. AI Drug Discovery Platforms Expected to Lead 60% of New Molecular Entities by 2026

    AI-driven platforms are projected to account for 60% of new molecular entities by 2026, a substantial rise from approximately 12% currently. These platforms are significantly accelerating drug discovery timelines, reducing the process from years to months or even hours for specific stages, and leading to higher quality drug candidates.

  22. New AI Software Detects Gallbladder Cancer Early; Genesis Molecular AI Secures Major Drug Discovery Deal

    Researchers have developed an AI software capable of detecting gallbladder cancer early through ultrasound images, analyzing multiple images to highlight areas of concern. Genesis Molecular AI has entered into a significant deal with Incyte, potentially worth over $1 billion, to advance AI-driven drug discovery. These developments highlight AI's growing role in early cancer detection and accelerating pharmaceutical research.

  23. FDA Launches AI Pilot Program for Clinical Trials; AI Tools Aid Pathologists and Drug Research

    The FDA has launched a pilot program using AI and data science tools to monitor clinical trials in real-time, with initial trials by AstraZeneca and Amgen underway. Stanford Medicine has developed an AI tool to help pathologists work faster and improve diagnostic accuracy, while Johns Hopkins Medicine is leveraging AI to accelerate cancer drug research and development.

  24. AI Detects Pancreatic Cancer Early, New Cancer Reprogramming Hypothesis Proposed

    A new theoretical paradigm, the Oncodarwinian Hypothesis, proposes reprogramming cancer cells using AI-based 3D printed p53 superproteins. Separately, an AI model can detect pancreatic cancer on routine CT scans significantly earlier than human radiologists, identifying 73% of pre-diagnostic cancers with a median lead time of approximately 16 months.

  25. AI advances in clinical trials, cancer detection, and drug development reported

    Medable launched Agent Studio for AI agents in clinical trials, while researchers developed AI-powered molecular sensors for early cancer detection. UC Riverside received an award for AI-enabled drug discovery, and the Institute of Cancer Research developed AI 'fingerprint' technology to speed up drug development.

  26. AI Accelerates Cancer Drug Development: Isomorphic Labs Raises Funds, Novo Nordisk Cuts Launch Times

    Isomorphic Labs, a spinout from Google DeepMind, is reportedly raising approximately $2.1 billion to accelerate AI-designed drug development, with plans for clinical trials by late 2026. Novo Nordisk is utilizing AI to reduce drug launch times by up to two-thirds, accelerating regulatory filings. The European Commission is also expanding its network of AI-powered medical screening centers for early cancer detection.

  27. Exogene Launches AI Lung Cancer Drug Development Crowdfunding; Grundium Acquires Visiopharm

    An Oxford-based biotech firm, Exogene, launched a crowdfunding campaign for its generative AI-driven personalized lung cancer drug development. Concurrently, Grundium acquired Visiopharm to create an integrated digital and computational pathology platform, and a new AI tool may personalize multiple myeloma treatment by detecting immune-related signals in bone marrow biopsy slides.

  28. EU Boosts AI for Cancer Screening; Companies Integrate AI in Drug Development

    The European Union is increasing its use of AI for early cancer screening, showing potential to improve detection rates for lung and prostate cancer by 20-30%. Recent developments highlight advancements in AI-powered drug discovery, pathology, clinical trial optimization, and cancer detection, with companies like Novo Nordisk, Merck, and Siemens integrating AI into their R&D processes.

  29. AI pathology platform created; ArteraAI Prostate Test launched; new screening tool developed

    Grundium Oy acquired Visiopharm A/S on May 21, 2026, to create an integrated precision pathology platform combining digital slide scanning with AI analysis. The ArteraAI Prostate Test is being clinically launched to personalize therapy intensity for patients with metastatic hormone-sensitive prostate cancer. Queensland scientists have developed a breakthrough AI screening tool for cancer detection, with clinical implementation planned within two years.

  30. FDA Grants Breakthrough Designation to AI for Bladder Cancer Risk Prognostication

    The FDA has granted Breakthrough Device Designation to Vesta Bladder Risk Stratify Dx, an AI-powered digital pathology assay designed to prognose bladder cancer risk. This designation aims to expedite the development and review of innovative medical devices, assisting pathologists in assessing the risk of bladder cancer recurrence or progression.

  31. Google AI shows improved accuracy in breast cancer detection in UK clinics

    Google's AI system for breast cancer detection has been tested in UK clinics, demonstrating higher accuracy and fewer false positives than initial human expert evaluations, and successfully identifying cancers missed by doctors. Separately, the University of Hong Kong developed a portable AI device for non-invasive cancer risk detection using saliva samples, which received a Gold Medal at the International Exhibition of Inventions of Geneva.

Show earlier developments (202 more)

OpenAI releases GPT-Rosalind for drug discovery; FDA pilots AI to cut trial times

OpenAI has released an early version of its AI model, GPT-Rosalind, designed to accelerate drug discovery and support life sciences research. The FDA is exploring the use of AI to shorten clinical trial timelines, with a pilot program aiming to potentially reduce overall trial time by 20-40% through causal AI and real-time monitoring.

New AI Tools Show Promise in Early Cancer Detection and Drug Discovery

A new AI-powered handheld endomicroscope, PrecisionView, has shown promise in identifying precancerous changes in cervical and oral tissues at the point of care. Separately, the REDMOD AI tool demonstrated nearly double the accuracy of specialists in detecting early-stage pancreatic cancer on standard scans, up to three years before clinical diagnosis. Companies like Recursion are also using AI to accelerate drug discovery and development, aiming to reduce failure rates.

New AI framework SPARK developed for tumor pathology data analysis

Scientists have developed SPARK, an agentic AI framework designed to autonomously analyze complex pathology data from tumors. This approach helps researchers uncover hidden biological information within tumors, aiming to accelerate cancer research by providing novel insights.

Argonne Lab Uses AI and Supercomputing for Cancer Drug Discovery

Argonne National Laboratory is using AI and high-performance computing in its IDEAL project to screen billions of molecular compounds, aiming to accelerate cancer drug discovery and vaccine development. The project has the potential to reduce development timelines from years to months. Additionally, the TRIALSCOPE framework, developed by Providence and Microsoft, has demonstrated success in replicating outcomes of lung and pancreatic cancer clinical trials.

AI Framework TRIALSCOPE and FDA Program Enhance Clinical Trials

Providence and Microsoft have partnered to create TRIALSCOPE, an AI-enabled framework designed to simulate clinical trials and more efficiently identify eligible participants. The U.S. Food and Drug Administration (FDA) is also piloting a 'real-time clinical trials' program aimed at improving the efficiency, speed, and quality of decision-making in early-phase trials.

Generative AI and AI-driven clinical trial tools advance cancer research and treatment

Generative AI models are emerging as powerful tools to understand cancer complexity by integrating image, molecular, and clinical data, potentially improving diagnostic accuracy and personalized therapies. Additionally, AI algorithms like TrialGPT are being developed to enhance clinical trial processes by improving patient recruitment and matching, addressing disparities in trial access.

AI Handheld Microscope and Pathology Tool Advance Cancer Detection

Researchers from Rice University and MD Anderson Cancer Center have developed PrecisionView, an AI-powered handheld endomicroscope for real-time diagnostics at the point of care. Separately, Australian scientists created STimage, an AI screening tool that enhances pathology by predicting cancer types and prognosis using spatial biology analysis, aiming for faster, more accurate diagnoses and improved access to specialist care.

Roche to acquire PathAI for up to $1.05 billion to boost AI diagnostics

Roche is acquiring PathAI, a company specializing in AI-powered digital pathology, for up to $1.05 billion. This strategic move aims to enhance Roche's capabilities in AI-driven diagnostics and companion diagnostics for oncology trials, ultimately improving cancer diagnosis and personalized treatment development.

New AI tool STimage uses spatial biology to detect hidden cancer markers

Scientists have developed an AI screening tool called STimage that uses spatial biology analysis to help pathologists detect hidden genetic markers of cancer in tissue samples. The tool has shown accuracy in predicting breast, skin, and kidney cancers, potentially leading to faster diagnoses and personalized treatments.

Johns Hopkins researchers develop AI tool to predict cancer immunotherapy response

Researchers at Johns Hopkins Medicine have developed a novel AI tool that analyzes complex biological data to predict patient response to cancer immunotherapy. The tool aims to personalize treatment by identifying the most effective immunotherapies for individual patients, thereby improving outcomes.

Mayo Clinic AI Model REDMOD Detects Pancreatic Cancer Years Before Diagnosis

A Mayo Clinic-developed AI model, REDMOD, has demonstrated the ability to detect pancreatic cancer on routine CT scans up to three years before clinical diagnosis. This advancement is part of broader progress in AI for cancer detection, pathology, and drug development, with AI models also being created to signal cancer presence via molecular sensors.

AI discovers first drug candidate for solid tumors; urine tests for early cancer detection developed

The UAE has announced the development of ISM0387, the first fully AI-discovered and developed drug candidate showing promise against solid tumors, including aggressive brain cancers. Researchers have also developed AI-generated molecular sensors capable of detecting cancer in its earliest stages through simple urine tests, offering potential for at-home diagnostics.

LG AI Research and Vanderbilt University Medical Center Develop AI System to Streamline Cancer Treatment

LG AI Research and Vanderbilt University Medical Center have developed an agentic AI system designed to streamline the entire cancer treatment workflow to a single day. New research also indicates Hologic's AI-driven breast cancer detection technologies can support radiologists, and an AI framework has been developed to predict PIK3CA mutations in breast cancer, potentially improving personalized treatment decisions.

HKUST develops new AI pathology system PRET for accurate cancer identification

The Hong Kong University of Science and Technology (HKUST) has developed PRET, a new AI pathology analysis system that accurately identifies multiple cancer types with minimal samples and without additional training. PRET demonstrated superior performance over existing methods in 20 out of 23 international benchmark datasets, achieving an Area Under the Curve (AUC) exceeding 97% in 15 tasks. Additionally, an AI-designed TNIK inhibitor has entered human testing, and Paradigm Health has launched an AI-powered platform to accelerate clinical trials.

Johns Hopkins Medicine's CAIA advances AI for brain cancer diagnosis and treatment

Johns Hopkins Medicine's Cancer AI Alliance (CAIA) is advancing AI-driven diagnosis and treatment for brain cancer, while a new study shows large language models can generate more comprehensive cancer pathology report summaries. Evaxion's AI-Immunology platform has also shown high precision in identifying targets for personalized cancer vaccines, with new data from a Phase 2 trial.

MedScan AI achieves 95% accuracy in early cancer detection, integrates into 1,000+ facilities

An AI system named 'MedScan AI' has achieved 95% accuracy in early cancer detection with a false positive rate below 3%, and is being integrated into over 1,000 healthcare facilities worldwide. Researchers have also developed an AI model that designs peptides for molecular sensors capable of detecting cancer-linked proteases in urine tests for early detection.

AACR Annual Meeting 2026 to feature AI in cancer research, EIC awards €118M for AI cancer diagnosis

The AACR Annual Meeting 2026 will feature AI in cancer research, with a Plenary Session on April 19, 2026. Generative AI has achieved diagnostic accuracy rates of 95%-98% for lung cancer, and AI in breast cancer screening has shown a 10.4% increase in detection, reducing notification times from 14 to 3 days. Additionally, generative AI for cancer diagnosis was among breakthrough projects awarded €118 million by the European Innovation Council on April 5, 2026.

OpenAI Launches GPT-Rosalind to Accelerate Drug Discovery

OpenAI has launched GPT-Rosalind to accelerate drug discovery by helping researchers extract insights from data. A new AI-powered method, PhenMap, has been developed to predict patient response to bowel cancer treatment, potentially sparing thousands from ineffective therapies.

AI accelerates drug discovery, improves medical imaging, and advances cancer detection

AI is accelerating drug discovery with tools like OpenAI's GPT-Rosalind and AWS's Amazon Bio Discovery, while the DELFI blood test shows promise for early detection of liver and lung cancers. New AI frameworks like ClAIrVue are improving medical imaging analysis, and AI-designed small molecules are advancing into clinical trials.

AI to Reshape Clinical Trials, Drug R&D, and Disease Screening by 2026

2026 is anticipated to be a pivotal year for AI in clinical trials, moving from exploration to execution, with AI expected to reshape trial design through simulation and the use of richer data. AI systems are also showing promise in identifying individuals at higher risk of melanoma by analyzing routine health data, paving the way for more targeted screening. Major pharmaceutical companies are transitioning to AI platforms for drug R&D, with generative AI producing small-molecule candidates advancing into human testing.

FDA approves first AI-based pathology product for prostate cancer detection

The FDA has approved Paige Prostate, the first AI-based pathology product for detecting cancer in prostate biopsies, significantly improving accuracy. A new AI tool, MangroveGS, can predict cancer spread with approximately 80% accuracy by analyzing gene patterns.

Ryght AI Launches Free AI-Powered Clinical Trial Site Search Engine

Ryght AI has launched the world's first free AI-powered clinical trial site search engine. This tool aims to accelerate cancer drug discovery, potentially reducing the process from a decade to months or years and saving billions of dollars.

Evaxion announces new phase 2 data for personalized cancer vaccine EVX-01

Evaxion A/S announced new phase 2 data for its personalized cancer vaccine EVX-01, with its AI-Immunology™ platform achieving an 86% success rate in identifying vaccine targets. Novartis CEO Vas Narasimhan joined the board of AI company Anthropic, and AbbVie is leveraging generative AI for drug discovery and clinical trial optimization.

ViewsML AI platform offers biomarker insights from pathology slides without staining

ViewsML's AI platform offers biomarker insights from pathology slides without staining, saving time and cost. Additionally, advanced AI models in a Swedish study accurately identified individuals with up to a 33% chance of developing melanoma within five years, paving the way for targeted screening.

Lantern Pharma launches AI co-scientist for rare cancer drug discovery

Lantern Pharma has launched withZeta.ai, an AI co-scientist for rare cancer drug discovery, and Amazon has introduced a system to generate and virtually test thousands of drug molecules. An AI-designed TNIK inhibitor has also shown safety and pharmacodynamic signals in a human trial, accelerating clinical translation.

NCCN updates breast cancer guidelines to include AI-based risk assessment

The National Comprehensive Cancer Network (NCCN) has updated its 2026 guidelines to incorporate AI-based risk assessment for breast cancer using mammogram data. The Clairity Breast AI model is the first FDA-approved tool for predicting 5-year breast cancer risk from mammography.

OpenAI Introduces GPT-Rosalind AI Model for Drug Discovery and Scientific Research

OpenAI has introduced GPT-Rosalind, an AI model designed to accelerate drug discovery and scientific research by analyzing large datasets. Bristol-Myers Squibb is collaborating with AI startups to optimize clinical trial design and protocol authoring. Additionally, FDA-authorized software is now assisting pathologists in identifying potential cancer in prostate biopsy images.

Waiv achieves dual CE marking under IVDR for AI precision tests for breast and colorectal cancer

Waiv has achieved dual CE marking under IVDR for its AI precision tests for breast and colorectal cancer, enabling clinical deployment across EU member states. These tests aim to improve patient outcomes through AI-driven prognostic risk profiling and MSI screening.

FDA Releases 10 Guiding Principles for AI in Drug Development

The FDA has released 10 guiding principles for AI in drug development, stressing the need for traceable and explainable logic. MIT and Microsoft researchers are developing AI-designed molecular sensors for early cancer detection, potentially enabling simple urine tests. Weill Cornell Medicine is also training researchers in AI fluency for oncology, emphasizing ethical use.

Lunit and Evaxion Present New AI Oncology Research at AACR Annual Meeting

Lunit and Evaxion are presenting new AI research in oncology, including AI-driven biomarkers and tumor microenvironment analysis, at the AACR Annual Meeting. AI is also being used to design molecular sensors for early cancer detection and to predict patient response to specific cancer treatments, aiming to personalize therapies and improve outcomes.

Researchers develop AI tool SIDISH to identify aggressive cancer cell groups

Researchers have developed a new AI tool called SIDISH that identifies specific cell groups within tumors driving aggressive cancers, offering a more targeted therapy approach. Amazon Web Services launched 'Amazon Bio Discovery,' an AI-powered platform to accelerate drug discovery. Additionally, an AI tool can now estimate biological age from chest X-rays, and another AI tool is being developed to predict patient response to bowel cancer treatment.

AI Magicx reports AI systems detect tumors 40% earlier; Insilico Medicine nominates AI-designed drug

AI systems are now detecting tumors 40% earlier than human radiologists, and pathology AI has achieved 94% diagnostic accuracy, according to AI Magicx. Insilico Medicine has nominated ISM6200, an AI-designed drug candidate, for the treatment of ovarian cancer and cortisol disorders. Tempus AI has introduced an automated clinical update service for its AI-enabled clinician portal to keep cancer therapy recommendations current.

Google AI proposes new cancer drug, Amazon launches Bio Discovery, study finds AI chatbots give bad medical advice

A study published in April 2026 demonstrated that AI models can identify high-risk melanoma patients, potentially leading to more efficient screening. Google's AI model has proposed and validated a new drug combination for cancer treatment, and Amazon launched 'Amazon Bio Discovery' to accelerate early-stage drug discovery. Separately, a study found AI-driven chatbots provide problematic medical advice about 50% of the time.

Study finds open-source AI models outperform physicians in summarizing cancer pathology reports

A study published on April 12, 2026, found that open-source AI models can generate more comprehensive summaries of cancer pathology reports than physicians, excelling at capturing critical molecular and genetic findings. Separately, an AI tool is under development to predict bowel cancer patient response to NHS drugs, and South Korea has seen a surge in AI-based medical device approvals, including one that generates medical reports. Additionally, an AI-based liquid biopsy shows promise for detecting brain cancer with about 75% accuracy.

AI Agents and Pfizer Advance Drug Discovery and Cancer Treatment with New Technologies

Emerging AI agents can autonomously optimize drug design and development, proposing therapeutic strategies and handling complex, multi-step problems in oncology. Additionally, a new AI-powered chemistry technique called "Chemputation" automates molecule creation for new medications, significantly speeding up drug discovery. Pfizer is also partnering with AI startups to discover new chemical structures for antibody-drug conjugates, aiming to enhance precision in developing advanced cancer treatments.

Daiichi Sankyo, Nexomic, and SeleneX advance AI in oncology for biomarker discovery, treatment, and early detection

Daiichi Sankyo is collaborating with Imagene AI to enhance biomarker discovery and predict treatment responses using multimodal AI. Nexomic has launched AI-driven precision oncology solutions for patient stratification and therapy selection. Additionally, SeleneX, a new clinical AI platform, has been introduced to detect ovarian cancer earlier and personalize treatment pathways.

Insilico Medicine nominates AI-developed drug candidate for ovarian cancer and cortisol disorders

Insilico Medicine has nominated ISM6200, a preclinical drug candidate for ovarian cancer and cortisol disorders developed using generative AI. Lantern Pharma is showcasing its withZeta.ai platform for rare cancer drug discovery. Additionally, AI tools are showing promise in increasing breast cancer detection rates by over 10% and predicting cancer spread with approximately 80% accuracy.

Ataraxis AI Launches New AI Test for Breast Cancer Treatment Prediction

Ataraxis AI has launched Ataraxis Breast NEO, a new AI test that predicts response to neoadjuvant therapy in early-stage breast cancer patients. Separately, a UK study found that AI software 'Mia' can increase breast cancer detection rates by over 10% and reduce healthcare professional workload. PathAI and MedStar Health have also partnered to implement AI-driven digital pathology platforms.

Insilico Medicine nominates ISM6200 for ovarian cancer, marking 29th nomination

Insilico Medicine has nominated ISM6200, a preclinical candidate targeting NR3C1 for ovarian cancer and other disorders, marking their 29th nomination. Caris Life Sciences launched an AI-driven tool to identify which non-small cell lung cancer patients benefit from chemotherapy. Additionally, a new AI tool shows promise in predicting recurrence for Barrett's esophagus patients.

Beijing Launches Initiative to Become Global Biomedical Innovation Hub

Beijing has launched a policy initiative to become a global hub for biomedical innovation, focusing on AI-driven drug discovery and surgical robots. New research indicates AI can detect cancer early through gut bacteria analysis and voice pattern changes.

Insilico Medicine Designs Dual-Action Cancer Drug Candidate Using Generative AI

Insilico Medicine has leveraged generative AI to design a dual-action cancer drug candidate targeting PKMYT1, capable of both eliminating the target protein and inhibiting its activity. Fortrea has launched Fortrea Intelligent Technology™ (FIT), an AI-enhanced suite of solutions designed to automate clinical trial workflows and improve oversight. Researchers at the University of Geneva have developed a new AI tool, MangroveGS, capable of predicting cancer spread with approximately 80% accuracy across multiple cancer types.

Researchers highlight AI 'mirages' in medical imaging, PathAI and MedStar partner on AI platform

Researchers are highlighting the phenomenon of AI "mirages" where models may fabricate findings in medical images, underscoring the need for rigorous evaluation frameworks. PathAI and MedStar Health are partnering to deploy an AI digital pathology platform to enhance diagnostic confidence and speed.

AI Explored for Cancer Detection and Precision Oncology

AI is being explored for detecting laryngeal cancer through voice analysis and for identifying liver and lung cancers via new blood tests. Generative AI and LLMs are also showing potential in precision oncology by aiding oncologists in interpreting genomic data and finding suitable clinical trials.

Huawei develops pathology AI model for high-accuracy cancer diagnosis

A dual-perspective AI model has achieved over 96% accuracy in early lung cancer diagnosis by analyzing CT scans from multiple viewpoints. Huawei has developed a pathology AI model that is in clinical use for high-accuracy cancer diagnosis across various types. Furthermore, AI-driven development has facilitated an FDA submission for neladalkib, an ALK-positive non-small cell lung cancer treatment.

Insilico Medicine uses generative AI to design dual-action cancer drug candidate

Insilico Medicine has utilized generative AI to design a dual-action cancer drug candidate targeting PKMYT1, a protein implicated in tumor growth. Eli Lilly has entered into a significant collaboration with Insilico Medicine for AI-driven drug discovery, and Roche has expanded its AI capabilities with Nvidia to accelerate therapeutic and diagnostic development.

AI Models Panda and Mia Demonstrate High Accuracy in Cancer Detection

The global market for AI in clinical trials is projected to reach $6.5 billion by 2030, with AI reshaping trials by improving safety monitoring and potentially shrinking sizes. A Chinese AI model, Panda, has shown 99.9% specificity and 92.9% sensitivity in detecting pancreatic cancer from CT scans, identifying early-stage cancers missed by doctors. Additionally, an AI tool named Mia successfully detected breast cancer earlier than human radiologists in a UK study.

Medmain Inc. unveils new AI model for detecting Ki-67-positive cells in pathology slides

Medmain Inc. has unveiled a new AI model for automatically detecting Ki-67-positive cells and calculating their labeling index in pathology slides, published on April 5, 2026. Experts predict AI will become foundational in clinical trials, potentially increasing enrollment by 10% to 20% and accelerating completion. Insilico Medicine announced promising preclinical results for its AI-designed CDK12/13 inhibitors targeting resistant cancers.

AI Model Identifies Breast Cancer Patients Who Can Safely Avoid Chemotherapy

An AI model can now analyze breast cancer pathology images to identify patients who can safely avoid chemotherapy, potentially sparing thousands from harsh side effects. Concurrently, there is a growing emphasis on developing robust data infrastructure to enable AI to unlock the complexities of cancer research.

AI Systems Function as Co-Scientists in Cancer Research, Generating Drug Candidates

AI systems are now functioning as 'co-scientists' in cancer research, generating drug candidates and guiding experimental design, with ChatGPT challenged to create cancer drugs. The European Innovation Council is funding generative AI projects for cancer diagnosis and treatment, while a new machine-learning model predicts molecular influence on gene expression for drug candidates targeting specific diseases.

AI tool Mia increases breast cancer detection by 10.4% and reduces notification times

The AI tool Mia has demonstrated a 10.4% increase in breast cancer detection rates and significantly reduced notification times for affected women. Insilico Medicine is showcasing four oncology programs discovered using its generative AI platform at AACR 2026, building on its partnership with Eli Lilly. Challenges in AI adoption for clinical trials persist, with a focus on building trust and maintaining human oversight.

Eli Lilly commits $2.75 billion to Insilico Medicine for AI-discovered drugs; Harvard develops AI cancer diagnosis tool

Eli Lilly has committed $2.75 billion to Insilico Medicine for AI-discovered drug candidates, signaling strong industry confidence in AI's role in accelerating pharmaceutical R&D. Harvard Medical School scientists have developed a new AI tool, CHIEF, capable of diagnosing cancer, predicting molecular profiles, and forecasting patient survival across multiple cancer types with high accuracy.

Clinical AI Launches MAIA™ Prescreening on Google Cloud Marketplace

Clinical AI has launched MAIA™ Prescreening on Google Cloud Marketplace, an AI-driven patient screening solution designed to expand patient access and accelerate clinical trial timelines. Technology Networks discusses how AI can be used to create synthetic control arms in clinical trials, simulating patient trajectories and predicting outcomes in silico, which could improve trial efficiency and success rates.

Lunit and CellCarta Partner to Accelerate AI-Enabled Digital Pathology Workflows

Lunit and CellCarta are partnering to accelerate AI-enabled digital pathology workflows for translational research, clinical trials, and companion diagnostic programs. Additionally, an AI-powered stroke clinical decision support system has demonstrated improved patient outcomes in a study.

Mass General Brigham AI Tool Reduces Clinical Trial Screening Time

A study at Mass General Brigham Health System found that an AI-assisted patient screening tool significantly reduced the time to determine clinical trial eligibility and enrollment. This highlights AI's growing role in clinical trials for improving efficiency in patient recruitment and screening.

AI model predicts liver cancer risk, revolutionizes melanoma detection

A machine learning model is now being used to predict liver cancer risk, outperforming existing tools with routine clinical data. Additionally, AI is revolutionizing melanoma detection and treatment through rapid image analysis and personalized approaches, though concerns about biases for darker skin tones are being addressed.

OneMedNet, Onco-Innovations, Inka Health collaborate on oncology drug development

OneMedNet Corporation has formed a strategic collaboration with Onco-Innovations and Inka Health to accelerate oncology drug development using real-world data and AI. Insilico Medicine announced that four of its abstracts, showcasing generative AI-discovered cancer inhibitors, were accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026.

UVA Scientists Develop AI Tools for Drug Discovery; EIC Funds Generative AI for Medical Diagnosis

Scientists at the UVA School of Medicine have developed a suite of AI tools, including YuelDesign, YuelPocket, and YuelBond, to accelerate drug discovery by designing molecules tailored to protein targets. Additionally, the European Innovation Council is providing funding to projects that utilize generative AI for medical diagnosis and cancer treatment, aiming to accelerate innovation in these critical healthcare areas.

Insilico Medicine advances generative AI in drug discovery with new therapy candidates

Insilico Medicine is advancing generative AI in drug discovery, showcasing a new therapy candidate for HR+/HER2- breast cancer and an MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. These advancements are part of their strategy to accelerate drug development.

Eli Lilly partners with Insilico Medicine for AI-designed drugs; FDA approves AI pathology product

Eli Lilly has entered a potential $2.75 billion partnership with Insilico Medicine for AI-designed preclinical drugs, and the FDA has approved Paige Prostate, the first AI-based pathology product for clinical use. OpenProtein.AI is also expanding its collaboration with Boehringer Ingelheim for AI-driven antibody discovery.

Drug Design for Global Health Platform Launches to Accelerate Drug Discovery

The Drug Design for Global Health (dd4gh) platform has been launched to accelerate drug discovery for diseases like malaria, and the Ataraxis Breast CTX AI test predicts individualized chemotherapy benefits for breast cancer patients. Additionally, the European COMPASS project is using AI to develop predictive models for early detection and personalized treatment of cardiotoxicity in cancer patients.

New AI system creates 3D cell maps for cancer detection, Bristol Myers Squibb partners with Faro for AI-powered clinical trials, and Kazakhstan launches AI radiology system.

A new AI system creates 3D digital maps of cells for faster, more accurate cancer detection, achieving near-perfect accuracy. Additionally, Bristol Myers Squibb has partnered with Faro to implement AI-powered workflows for improving clinical trial protocols, covering design, drafting, validation, and optimization. An AI-based radiology information system has also been launched in Kazakhstan's Kyzylorda region, capable of detecting tumors as small as 1 millimeter.

Lunit and CellCarta Partner to Advance AI-Enabled Digital Pathology for Diagnostics

Lunit and CellCarta have partnered to accelerate AI-enabled digital pathology for companion diagnostic programs, combining Lunit's AI algorithms with CellCarta's CDx development capabilities. Discovery Life Sciences and Mindpeak have also partnered to advance AI-powered digital pathology for biomarker analysis in global clinical trials. Additionally, an AI model named PRE-Screen-HCC has been developed to predict liver cancer risk with nearly 80% accuracy.

SEQSTER PDM, Spotlight Pathology, and University of Utah advance AI in healthcare

SEQSTER PDM, Inc. released "1-Click Eligibility," an AI solution to rapidly identify clinical trial participants, accelerating drug development timelines. Spotlight Pathology received £1.4 million in seed funding for its AI software that analyzes digital pathology images for early blood cancer identification. Scientists at the University of Utah created an AI-powered "lab-on-a-chip" device to predict cancer cell sensitivity to targeted therapies for pediatric leukemia.

Servier partners with Insilico Medicine in $888M deal to develop AI-driven oncology therapies

New AI-based liquid biopsies are showing promise for detecting brain, liver, and lung cancers in early stages by analyzing DNA and immune system signals. The generative AI in clinical trials market is projected to reach nearly USD 2 trillion by 2035, driven by the demand for accelerated drug development. Servier has partnered with Insilico Medicine in an $888 million deal to discover and develop oncology therapies using AI.

Google AI's Cell2Sentence-Scale model proposes and validates new cancer drug combination

Google AI's Cell2Sentence-Scale model has proposed and validated a new cancer drug combination, while Purple Biotech is using generative AI to design novel tri-specific antibodies for oncology. Hoth Therapeutics has also launched its AI platform, OpenClaw, to accelerate drug discovery.

University of Chicago researchers develop AI system for diagnosing rare tumors; Pictor Labs launches virtual staining system

Researchers at the University of Chicago have developed a new AI-powered system to assist pathologists in diagnosing rare thymic epithelial tumors, potentially improving treatment decisions. Pictor Labs has also launched an on-premises AI virtual staining system, allowing pathology labs to generate digital stains locally.

BostonGene, myTomorrows, and Tempus advance AI in oncology and drug development

BostonGene showcased its AI-driven disease modeling platform at JSMO 2026 to accelerate drug development and precision oncology. myTomorrows and Clínica Universidad de Navarra partnered to enhance AI-powered clinical trial infrastructure in Spain, aiming to improve patient access to treatments. Tempus and Daiichi Sankyo are collaborating to develop AI models specifically for antibody-drug conjugate (ADC) development.

SCL Science develops cancer vaccines using AI platform, plans IND application by 2027

SCL Science is developing cancer vaccines using its AI platform, DeepNeo, with plans to submit an Investigational New Drug (IND) application by 2027. The AI in Pathology market is projected to reach approximately $1.39 billion by 2025, and the AI in Clinical Trials market is expected to grow at a CAGR of 22.6%.

New AI Tools Enhance Cancer Diagnosis and Treatment, Improve Mammography Accuracy

New AI tools are enhancing cancer diagnosis and treatment by improving mammography accuracy and reducing radiologist workload. AI models can now predict cancer metastasis with approximately 80% accuracy and assess immunotherapy response in metastatic breast cancer, potentially guiding treatment decisions.

Purple Biotech, RyboDyn, and Tempus AI Advance AI in Biotech and Pharma

Purple Biotech is collaborating with Converge Bio to use generative AI for designing and optimizing novel tri-specific antibodies, aiming to significantly reduce discovery timelines. RyboDyn has secured seed funding to advance its AI-powered sequencing and discovery platform for identifying new cancer targets, while Tempus AI is partnering with Daiichi Sankyo to leverage AI for clinical development.

Discovery Life Sciences and MindPeak Partner to Integrate AI into Cancer Biomarker Testing

Discovery Life Sciences and MindPeak are partnering to integrate AI precision into cancer biomarker testing for global clinical trials, aiming to optimize patient selection and enhance diagnostic workflows. AI models are projected to increase trial enrollment by 10% to 20% by eliminating assessment biases and accelerating drug development through agentic AI.

Lantern Pharma and Roche utilize AI to accelerate cancer drug and diagnostic development

Lantern Pharma is using AI and big data to reduce cancer drug development time by up to 80%, while Roche has launched a large-scale 'AI factory' with thousands of NVIDIA GPUs to accelerate drug and diagnostic development. New AI-generated sensor systems are being developed to detect cancer early by identifying cancer-linked enzymes, potentially enabling at-home tests, and AI-powered blood tests are emerging for early detection by analyzing DNA fragments and immune system signals.

PharmaMar and Globant Launch AI Framework for Oncology Research; Michigan State Develops Gene-Focused ML

PharmaMar and Globant have launched a multi-agent AI framework to accelerate oncology research and drug development, reportedly achieving over 90% accuracy and reducing insight time by up to 15-fold. Researchers at Michigan State University have developed a gene-focused machine learning approach that predicts chemical influences on gene expression, leading to the identification of promising therapeutics for aggressive liver cancer and a chronic lung disease.

New AI system developed to reduce pathologist workload in cancer diagnosis

A new AI system has been developed to reduce the workload of pathologists in cancer diagnosis while maintaining high accuracy. Additionally, a machine learning system is accelerating drug discovery by accurately predicting chemical reaction outcomes, and the MAGIC AI system is being used for early cancer detection by analyzing micronuclei for chromosomal defects.

Recursion Pharmaceuticals uses AI to advance cancer drug to clinical testing in 18 months

Recursion Pharmaceuticals utilized its AI platform to advance a cancer drug candidate into clinical testing in 18 months, significantly shortening the typical 42-month timeline. Tools like DeepMind's AlphaFold are also aiding in the search for viable compounds. This acceleration is crucial for faster delivery of new cancer treatments to patients.

Servier Partners with Insilico Medicine and Iktos to Accelerate AI-Driven Oncology Drug Discovery

Servier is forming strategic partnerships with companies like Insilico Medicine and Iktos to accelerate therapeutic innovation and identify new oncology drug candidates using AI. A review also highlights how AI is optimizing drug delivery and pharmacokinetic modeling in polymer-based cancer therapies, enabling precise drug release and individualized treatment.

Journal of Hematology & Oncology Reviews Generative AI's Role in Precision Oncology

A review in the Journal of Hematology & Oncology explores how generative AI can assist oncologists in precision oncology by interpreting genomic mutations and identifying suitable clinical trials. The review highlights AI models' strong performance in clinical trial matching, with one model, TrialGPT, achieving 87.3% agreement with expert assessments.

Google AI outperforms human radiologists in breast cancer detection in NHS study

A Google AI system has demonstrated superior performance in detecting breast cancer compared to human radiologists in an NHS study, identifying more invasive cancers and 25% of interval cancers. Separately, a new AI system called MAGIC can automatically identify cells with early signs of chromosomal abnormalities linked to cancer development, speeding up research. Additionally, a medically trained AI system achieved 96% accuracy in identifying eligible patients for a rare disease clinical trial by analyzing EHR data.

Scientists develop AI system MangroveGS to predict tumor spread with 80% accuracy

Scientists have developed an AI system, MangroveGS, that analyzes gene-expression signatures to predict tumor spread with nearly 80% accuracy in colon cancer, and this system also identified gene signatures that predict metastatic potential in other cancers. Separately, agentic AI tools are being utilized to autonomously accelerate drug development processes, from candidate design to reducing clinical trial bottlenecks, aiming to improve research accuracy and reduce failure rates.

Medidata unveils AI-based virtual companions and new imaging biomarker for cancer treatment

A new AI imaging biomarker, the Quantitative Vessel Tortuosity (QVT™) score, can predict patient outcomes and detect early signs of treatment response in non-small cell lung cancer. Additionally, Medidata has unveiled a suite of AI-based virtual companions designed to accelerate drug development and improve patient care in the life sciences industry.

AI improves breast cancer screening and clinical trial matching

New research indicates that AI in breast cancer screening can detect more invasive cancers and overall cases, with fewer false positives and recalls compared to human readers, and reduced scan reading time. Additionally, a new AI-based technology called DocTr has demonstrated superior performance in matching doctors and clinical trial sites to studies.

UK Study Finds AI Increases Breast Cancer Detection by 10.4% and Reduces Workload

A UK study published in Nature Cancer found that AI can increase breast cancer detection by 10.4% and potentially reduce healthcare worker workload by over 30%, with notification times reduced from 14 days to 3 days. Google's AI system also demonstrated improved breast cancer detection accuracy and reduced radiologist workload in UK trials. These advancements aim to assist radiologists in earlier and more accurate cancer detection.

AI predicts breast cancer detection and unravels cancer mechanisms for new therapies.

A study presented at the European Congress of Radiology indicates that AI assessment of screening mammograms can predict the likelihood of breast cancer detection in subsequent screenings. Separately, artificial intelligence is being used to unravel complex cancer mechanisms, leading to new targeted therapies and personalized treatment plans by analyzing vast amounts of cancer data to uncover hidden patterns.

PathAI receives FDA Breakthrough Device Designation for AI skin lesion tool; Medidata deploys AI for Menarini Group oncology trials

PathAI has received U.S. FDA Breakthrough Device Designation for PathAssist Derm, an AI tool designed to analyze skin lesions. Additionally, Medidata is deploying its AI Study Build technology to accelerate oncology clinical trials for The Menarini Group, aiming to reduce trial startup times.

Scientists develop AI systems to detect cancer and predict tumor metastasis with high accuracy

Scientists have developed an AI system called MangroveGS that analyzes gene-expression signatures to predict tumor metastasis with nearly 80% accuracy in colon cancer. Separately, an AI-powered "electronic nose" developed at Linköping University can detect early signs of ovarian cancer in blood samples with 97% accuracy by analyzing volatile substances. USC researchers also created an AI algorithm that automates the detection of rare cancer cells in blood samples in approximately 10 minutes.

Xlue Inc. develops AI tool to identify high-risk cancer patients

Xlue Inc., a startup from Carnegie Mellon University, is using artificial intelligence to identify patients at high risk for lung, liver, and pancreatic cancers. Their AI tool, CATCH-FM, is trained on millions of patient medical records to detect early signals of cancer development. The predictive technology aims to allow doctors to recommend earlier screenings, improving the chances of successful treatment, and has shown a 50% accuracy rate for predicting cancer in patients with no prior history.

Northeastern University develops AI tool for rapid leukemia diagnosis and treatment suggestions

Northeastern University has developed an AI tool that can diagnose acute myeloid leukemia (AML) and suggest treatments in as little as one night, potentially cutting down diagnosis-to-treatment time from weeks to a single day. Stanford Medicine has also created Nuclei.io, an AI-based tool designed to increase pathologists' speed, collaboration, and diagnostic accuracy. Additionally, Indian medtech firms are advancing AI diagnostic tools for conditions like brain damage, tuberculosis, and early breast cancer detection.

Indian Medtech Firms Develop AI Diagnostic Tools, Cleveland Clinic and Dyania Health Achieve 96.2% Accuracy in Rare Disease Trial Identification

Indian medtech firms are developing AI diagnostic tools for conditions like brain damage, tuberculosis, and early breast cancer detection. Additionally, an AI-driven system from Cleveland Clinic and Dyania Health has demonstrated a 96.2% accuracy in identifying patients for rare disease clinical trials, significantly improving diversity in participant recruitment.

Arc Institute Researchers Develop Evo 2 AI Model for Decoding DNA and Analyzing Cancer Genes

Researchers at the Arc Institute have developed Evo 2, a biological foundation model trained on 9 trillion DNA base pairs, capable of decoding DNA rules and generating new functional sequences. This AI model accurately predicts the effects of complex mutations and shows promise in analyzing cancer-related genes such as BRCA1. The development opens possibilities for programmable biology and enhanced cancer research.

MIT and Microsoft researchers develop AI for molecular sensors in cancer detection

Researchers at MIT and Microsoft have developed an AI model to design molecular sensors for early cancer detection, potentially usable in a urine test. New research from the University of Warwick warns that many AI pathology tools may rely on 'shortcut learning' rather than genuine biological understanding, raising concerns about reliability. Additionally, a Northeastern University AI tool can analyze patient samples to map genetic mutations and suggest treatments for acute myeloid leukemia (AML) in as little as one night.

Taiwanese Researchers Develop AI Platform PanMETAI for Early Pancreatic Cancer Detection

Researchers in Taiwan have developed PanMETAI, an AI-powered platform that detects early-stage pancreatic cancer with up to 94% accuracy using metabolic fingerprints from blood samples. Published in Nature Communications, the tool combines AI with NMR metabolomics to identify subtle metabolic shifts indicative of the disease. This non-invasive method aims to improve the notoriously low survival rate of pancreatic cancer through earlier diagnosis and treatment.

Russian Researchers Develop AI for Early Breast Cancer Detection from CT Scans

Russian researchers have developed a neural network capable of detecting early-stage breast cancer from CT scans in minutes. The AI system, created by St. Petersburg Electrotechnical University and the Almazov National Medical Research Center, highlights potential cancer signs for physician review and developers claim it reduces clinical error probability by approximately 20%.

Northeastern University develops AI tool for AML mutations; PanMETAI detects pancreatic cancer.

A new AI tool from Northeastern University can map AML genetic mutations to potentially reduce diagnosis-to-treatment time, while a study warns that some AI pathology models may use unreliable 'shortcut learning.' Separately, an AI blood test developed in Taiwan, PanMETAI, detects early-stage pancreatic cancer with over 90% accuracy.

Fred Hutch Researchers Test AI Platform to Accelerate Cancer Research

Researchers at Fred Hutch Cancer Center are testing a collaborative AI research platform designed to accelerate cancer research and develop AI models for predicting cancer progression, treatment effectiveness, and resistance mechanisms. The platform uses de-identified clinical data from member institutions to train these models, aiming for faster diagnoses and more precise therapies, particularly for rare cancers, while safeguarding patient privacy.

Researchers develop AI molecular sensors for cancer detection; FDA grants breakthrough to PathAI

Researchers have developed AI-designed molecular sensors for early cancer detection, with potential for at-home urine tests. The FDA granted breakthrough designation to PathAI's AI-powered dermatopathology solution, PathAssist Derm. However, new research suggests some AI pathology tools may rely on 'shortcut learning,' raising concerns about their reliability.

MIT and Microsoft Researchers Develop AI Molecular Sensors for Early Cancer Detection

Researchers at MIT and Microsoft have developed AI-designed molecular sensors for early cancer detection, with potential for home use. PathAI received FDA breakthrough designation for its AI-powered dermatopathology solution, PathAssist Derm. Additionally, a new AI tool from Northeastern University can map AML genetic mutations and predict drug resistance, aiming to significantly reduce diagnosis-to-treatment time.

FDA approves Claire, first AI-imaging device for breast cancer margin assessment

The FDA has granted pre-market approval to Claire, the first AI-imaging device in the U.S. for intraoperative breast cancer margin assessment during surgery. Separately, an Australian AI tool named BRAIx has shown higher accuracy than traditional factors in predicting breast cancer risk within four years using mammograms.

Australian AI Tool BRAIx Predicts Breast Cancer Risk with High Accuracy

An Australian AI-based tool, BRAIx, can now predict a woman's breast cancer risk within four years using mammograms with higher accuracy than traditional factors. Separately, Vanderbilt Health and Bertis have formed a collaboration to advance cancer drug discovery using AI-driven proteomics and molecular AI initiatives.

New research raises concerns about reliability of AI cancer pathology tools

Australian research indicates an AI-based tool, BRAIx, can predict a woman's risk of developing breast cancer within the next four years using mammograms with higher accuracy than traditional factors. A world-first trial in Sweden has shown that AI can help doctors identify more breast cancer cases during routine screenings by analyzing mammograms and flagging abnormalities. However, new research suggests many AI cancer pathology tools may rely on 'shortcut learning' rather than genuine biological signals, raising concerns about their reliability.

PathAI Receives FDA Breakthrough Device Designation for AI Skin Lesion Tool

PathAI received U.S. FDA Breakthrough Device Designation for PathAssist Derm, an AI tool designed to analyze skin lesions. LG CNS is expanding its AI applications in the pharmaceutical and digital health sectors, investing in CHA Biotech and developing an AI-based clinical trial design platform. These advancements aim to accelerate drug development and improve diagnostic workflows.

Perimeter Medical Imaging AI's 'Claire' Receives First FDA Approval for AI-Enabled Breast Cancer Surgery Device

Perimeter Medical Imaging AI's 'Claire' has become the first FDA-approved AI-enabled imaging device for breast cancer surgery. The device uses AI and wide-field OCT imaging for real-time evaluation of excised tumor margins. The pivotal trial demonstrated an 88.1% margin accuracy and a statistically significant reduction in patients with residual cancer post-surgery.

Vanderbilt Health and Bertis launch collaboration for cancer drug discovery; Northeastern AI tool aims to speed AML diagnosis; University of Warwick research raises AI pathology concerns

Vanderbilt Health and Bertis have launched a collaboration to advance cancer drug discovery by integrating proteomics and AI. A new AI tool from Northeastern University aims to drastically reduce acute myeloid leukemia (AML) diagnosis and treatment planning time from weeks to a single night by mapping genetic mutations. Additionally, research from the University of Warwick highlights concerns that AI pathology models may rely on 'shortcut learning,' potentially leading to unreliable predictions in patient care.

Northeastern University researcher develops AI tool to reduce AML treatment determination time

Northeastern University researcher Kiran Vanaja has developed a new AI tool designed to significantly reduce treatment determination time for acute myeloid leukemia (AML). The tool can diagnose AML, map genetic mutations, suggest potential drugs, and predict drug resistance, potentially cutting the time from diagnosis to treatment from weeks to a single night.

AI pipeline predicts neoplasia risk; University of Warwick warns of AI 'shortcut learning' in cancer pathology

New research indicates an AI pipeline using large language models can accurately predict the future risk of advanced neoplasia in patients with colitis-associated low-grade dysplasia. Separately, research from the University of Warwick warns that many AI tools for cancer pathology may rely on 'shortcut learning' rather than genuine biological signals, potentially impacting diagnostic reliability.

PathAI's AI-powered pathology solution, PathAssist Derm, receives U.S. FDA Breakthrough Device Designation

PathAI announced its AI-powered pathology solution, PathAssist Derm, received U.S. FDA Breakthrough Device Designation for analyzing skin lesions. Separately, research highlights concerns that AI pathology tools may use 'shortcut learning' rather than genuine biological signals, potentially impacting reliability. AI is also transforming drug development, with AI-enabled discovery workflows projected to reduce early timelines by up to 40% and costs by 30%.

Northeastern University develops AI tool for rapid leukemia diagnosis and treatment

Generate:Biomedicines has completed a $425 million IPO on the Nasdaq to advance AI-powered drug development, with CEO Mike Nally emphasizing biology's role in unlocking AI's potential. Northeastern University has developed a patented AI tool that can diagnose acute myeloid leukemia, map its genetic mutations, and suggest treatments, potentially reducing diagnosis-to-treatment time from weeks to a single night.

Northeastern University develops AI tool for acute myeloid leukemia diagnosis and drug resistance prediction

Vanderbilt Health and Bertis have launched a collaboration to advance AI, spatial biology, and translational cancer research for drug discovery. Northeastern University has developed a new AI tool that can diagnose acute myeloid leukemia, map its genetic mutations, and predict drug resistance, potentially reducing diagnosis-to-treatment time. Additionally, MD Anderson Cancer Center will host a discussion on the responsible implementation of AI innovations in oncology.

Researchers develop AI-powered cancer detection methods, including sensors and automated cell identification

Researchers have developed AI-generated sensors using peptides and nanoparticles that can detect specific cancer types based on protease markers, potentially enabling simple at-home urine tests. Scientists are also using AI to design custom proteins that guide immune cells to target cancer, a promising form of immunotherapy. Additionally, an AI algorithm can now automate the detection of rare cancer cells in blood samples within approximately 10 minutes, significantly speeding up liquid biopsy processes.

Researchers develop AI-generated sensors for cancer detection; study warns of AI diagnostic reliability

Researchers have developed AI-generated sensors using peptides and nanoparticles for earlier cancer detection, potentially identifying specific cancer types based on protease markers. A new study warns that many AI cancer diagnostic tools may rely on 'shortcut learning' rather than genuine biological signals, raising concerns about their reliability for patient care.

Scientists use AI to design custom proteins for cancer immunotherapy, while new AI system recommends treatments with high accuracy.

Scientists have used AI to design custom proteins that guide immune cells to target cancer cells, showing promise in immunotherapy. A new AI system can recommend cancer treatments based on tumor genetics with over 90% accuracy compared to expert clinicians. However, research also warns that some AI cancer tools may rely on 'shortcut learning' rather than true biological signals, potentially impacting reliability.

MSD uses AI to double drug candidates; USC and UCLA researchers develop AI for cancer detection and pathology

Merck Sharp & Dohme (MSD) is using AI models TEDDY and KERMT to accelerate drug design, doubling their promising drug candidates with two new molecules entering clinical trials. Researchers at USC have developed an AI algorithm that automates the detection of rare cancer cells in blood samples via liquid biopsy, identifying cancer cells in approximately 10 minutes. UCLA researchers created an AI tool, AQuA, to detect errors in digital pathology images, achieving 99.8% accuracy.

Generate Biomedicines raises $400M in IPO; Jeeva Clinical Trials urges AI infrastructure modernization

Generate Biomedicines, an AI-driven drug developer, has raised $400 million through its U.S. initial public offering to advance its platform for protein-based therapeutics. Concurrently, Jeeva Clinical Trials is urging the life sciences industry to modernize infrastructure to fully leverage AI in drug development, emphasizing that unified systems are crucial for AI's effectiveness.

Estonia integrates AI into healthcare; Roche uses AI for drug discovery

Artificial intelligence is being integrated into healthcare in Estonia for diagnostics in neurology, pathology, and ophthalmology. A review highlights AI's promise in improving oral cancer diagnosis, while Roche is leveraging AI and machine learning to accelerate drug discovery timelines and reduce costs.

Clearnote Health launches enhanced AI-powered Avantect Pancreatic Cancer Test

Clearnote Health has launched its enhanced Avantect Pancreatic Cancer Test, an AI-powered blood test designed to detect pancreatic cancer in high-risk individuals. The test analyzes blood samples for cancer-related molecules, using AI models to calculate a patient's risk level. In high-risk patients, the Avantect test shows an 82.6% sensitivity and 97.5% specificity for cancer detection.

Researchers develop AI for early cancer detection and immune cell guidance; Biorce secures $52.5M funding

Researchers have developed AI models to design molecular sensors for early cancer detection, potentially detectable through urine tests. Additionally, AI is being used to design proteins that guide cancer-fighting immune cells, and AI assistance has been shown to improve the detection of cancers on digital breast tomosynthesis images. Biorce also secured $52.5 million in Series A funding to advance its AI technology for clinical trials.

UC San Diego Researchers Develop AI Tool for Precise Urethra Mapping in Prostate Cancer MRI

UC San Diego researchers have developed a new AI tool that precisely maps the urethra on MRI scans to improve the safety and reduce urinary side effects of prostate cancer radiation therapy. The AI tool demonstrated performance comparable to or exceeding human experts, accurately identifying 81% of the true urethra compared to 34% by physicians in testing.

WuXi XDC and Earendil Labs form $885 million strategic collaboration for AI-driven ADC development

WuXi XDC and Earendil Labs have entered a strategic collaboration potentially valued at $885 million, combining WuXi XDC's antibody-drug conjugate (ADC) technology with Earendil's AI-driven antibody discovery platform. Earendil will license WuXi XDC's proprietary WuXiTecan-2 payload-linker technology to develop ADC candidates for cancer and autoimmune diseases. This partnership aims to accelerate the development of next-generation ADCs by leveraging Earendil's AI capabilities for antibody discovery.

Researchers explore AI tools for early cancer detection and improved treatment

Researchers are exploring AI-based tools to identify women at higher risk for breast cancer, potentially detecting cancers missed by standard mammograms by analyzing subtle imaging features. Additionally, AI models are being developed to design molecular sensors for early cancer detection through urine tests and to guide cancer-fighting immune cells to target cancer cells more effectively.

Northwell Health develops AI tool iNav, halving pancreatic cancer diagnosis time

Northwell Health has developed an AI clinical tool named iNav that significantly accelerates the detection and treatment of pancreatic cancer. A study published in The Oncologist revealed that iNav can cut the time from biopsy to diagnosis in half, from 12 days to six days, and also reduced the wait time for an oncologist appointment and treatment initiation.

Researchers develop AI system MAGIC to track genetic mishaps in living cells for cancer detection

Researchers have developed an AI system called MAGIC to track genetic mishaps within living cells that may lead to cancer, combining microscopy, AI image analysis, and genomic sequencing. Additionally, AI models are being used to design molecular sensors for early cancer detection via at-home urine tests. Labcorp is also expanding its collaboration with PathAI to deploy an AI-powered digital pathology platform across its U.S. labs.

Scientists develop AI and 3D technology for improved cancer cell detection

An international team of scientists has developed a new method using AI and 3D technology to improve the detection of cancer cells, particularly for cervical cancer. This AI-driven approach automates the analysis of cervical cell samples, offering a more precise and efficient alternative to traditional methods like the Pap smear test. The method promises to revolutionize cervical cancer diagnosis by accelerating the process and potentially leading to earlier life-saving treatment.

Researchers develop AI-powered electronic nose for early ovarian cancer detection

Researchers have developed an electronic nose utilizing machine learning and AI to detect early signs of ovarian cancer from blood samples, a method that could be adapted for various cancers. Additionally, an AI-based tool is being investigated at UMass Chan Medical School to identify women at higher risk for breast cancer by analyzing subtle imaging features missed by standard mammograms.

AI Demonstrates Faster Medical Data Processing and 97% Accuracy in Ovarian Cancer Detection

Generative AI has demonstrated the ability to process vast medical datasets significantly faster than human research teams, potentially yielding stronger results. In Australia, AI is poised to offer productivity gains in pathology, including augmented diagnostics and faster turnaround times for complex testing. Furthermore, an AI-powered electronic nose has achieved 97% accuracy in detecting early signs of ovarian cancer from blood samples.

Rakovina Therapeutics Increases Financing to CA$2.0 Million for AI-Driven Cancer Drug Programs

Rakovina Therapeutics Inc. has increased its financing to approximately CA$2.0 million to advance its AI-driven cancer drug programs. The company's collaboration with NanoPalm combines Rakovina's AI-enabled drug discovery with NanoPalm's delivery platform. Planned milestones for 2026 include joint venture funding and pursuing partnerships for antibody drug conjugate payloads.

iCAD's ProFound AI Suite increases cancer detection by 23% in mammograms

iCAD's ProFound AI Suite, a new AI-powered mammogram technology, has demonstrated a 23% increase in cancer detection rates and a reduction in false positives. Radiologist Dr. Kenneth Meng stated that AI is revolutionizing mammography and early breast cancer detection. The AI tool analyzes mammograms to highlight suspicious areas and reassure radiologists about benign regions, with a study involving over 100,000 breast imaging exams.

Caris, IIT Indore, and Researchers Advance Cancer Detection with AI Innovations

Caris has launched a proprietary AI Insights Signature that uses AI and machine learning to better understand patient responses to oral chemotherapy drugs for breast cancer. Researchers at IIT Indore have developed an AI system that analyzes medical images to improve early detection of breast and cervical cancer, identifying suspicious areas and reducing missed diagnoses. A study published in the Journal of the American College of Radiology indicates that AI assistance significantly increases cancer detection rates on screening digital breast tomosynthesis images, leading to a nearly 22% rise in detection.

Researchers develop AI models for early cancer detection and antitumor molecule design

Researchers have developed AI models to create molecular sensors for early cancer detection, potentially enabling at-home urine tests for lung, ovarian, and colon cancers. AI has also been utilized to design new molecules with potential antitumor activity, identifying compounds that show significant cytotoxic activity against tumor cells. Additionally, advanced AI systems are being developed to rapidly analyze medical images for improved early detection of breast and cervical cancer.

Epredia and Mindpeak Partner to Distribute AI Software for Digital Pathology in EU

Epredia and Mindpeak have entered into a distribution agreement to offer Mindpeak's AI image recognition software to Epredia's digital pathology customers in the European Union, aiming to enhance precision and speed in diagnostic image review. Concurrently, a review highlights the integration of AI and machine learning with chemoinformatics to identify and validate natural products for treating cancer metastasis and chemoresistance.

Researchers develop AI-generated sensors and AI-powered electronic nose for early cancer detection

Researchers have developed AI-generated sensors using peptides that can signal the presence of cancer-linked proteases, potentially leading to at-home urine tests for early cancer detection. Additionally, an AI-powered electronic nose can detect early signs of ovarian cancer in blood samples with 97% accuracy by analyzing volatile substances emitted by cancer cells.

AI Improves Cancer Detection and Accelerates Medical Image Annotation

AI assistance in digital breast tomosynthesis (DBT) has shown an increase in detecting invasive and lobular cancers, as well as smaller tumors. Researchers have also developed AI-generated sensors that can detect cancer-linked proteases, paving the way for early-stage detection through simple urine tests. Additionally, a new AI-based tool from MIT can rapidly annotate medical images, potentially accelerating clinical research.

Labcorp expands collaboration with PathAI to deploy AISight® Dx digital pathology platform

Labcorp announced an expanded collaboration with PathAI to deploy the FDA-cleared AISight® Dx digital pathology platform across its national network of labs and hospital collaborations. This platform utilizes AI to support diagnostic processes, enhance case management, and improve slide review and collaboration. The expansion includes AI-driven clinical trial support.

AI tools increase cancer detection rates by 22% in breast radiologists without raising false positives

A real-world study found that AI tools, used with 3D mammography across four sites, increased cancer detection rates by nearly 22% among breast radiologists without raising false positives. Telefónica, Fundación Vithas, and Francisco de Vitoria University are pioneering a project using quantum computing and AI to design cancer drugs targeting the BRAF V600E mutation, showing preliminary results of improved molecular candidates. Additionally, AI is being used to design proteins that act as a 'GPS' for T cells to more effectively locate and target cancer cells.

Researchers develop AI 'fingerprint' technology to assess cancer drug responses with high accuracy

Researchers have developed a new AI 'fingerprint' technology that analyzes changes in cancer cell shape to assess drug responses, potentially halving cancer drug development time with up to 99.3% accuracy. Additionally, a low-cost AI model can screen cervical cancer samples in 30 seconds, and human-AI teams have shown improved accuracy in identifying eligible patients for cancer clinical trials.

Study finds AI improves invasive and lobular cancer detection on breast tomosynthesis

A study published on February 20 in the Journal of the American College of Radiology indicates that AI assistance significantly improves the detection of invasive and lobular cancers on screening digital breast tomosynthesis (DBT) images. The AI-enhanced interpretation led to the identification of more small-sized cancers, particularly in dense breasts.

Evogene and QUT Partner for AI-Driven Cancer Drug Discovery

Evogene and Queensland University of Technology (QUT) have partnered to accelerate the discovery of AI-driven small molecule cancer therapeutics, focusing on overcoming resistance to chemotherapy and targeted therapies. Insilico Medicine and Eli Lilly have also published a vision for fully autonomous "Prompt-to-Drug" pharmaceutical R&D, outlining how AI can streamline the entire drug discovery pipeline.

University of Maine Researchers Develop AI Tool for Enhanced Breast Cancer Detection

Researchers at the University of Maine have developed a new AI tool called the Context-Guided Segmentation Network (CGS-Net) to enhance early breast cancer detection by analyzing digital breast tissue images and considering surrounding tissue for a more comprehensive analysis. Pathology News also highlights recent developments in AI-enhanced imaging for cancer detection and new digital pathology methods, focusing on improving accuracy and efficiency in analyzing tissue samples.

International Research Team Develops M-PACT AI for Brain Tumor Classification

An international research team has developed M-PACT, a new AI-based analysis method that accurately classifies brain tumors and monitors disease progression using genetic material from cerebrospinal fluid. The tool analyzes cell-free DNA fragments to identify characteristic molecular patterns for tumor classification. This development was reported on February 20, 2026.

Isomorphic Labs Launches IsoDDE Engine, Doubling AlphaFold 3's Accuracy in Protein-Ligand Prediction

Isomorphic Labs, an Alphabet company, has launched its AI-driven IsoDDE engine, a significant advancement in cancer drug discovery. This engine reportedly achieves double the accuracy of AlphaFold 3 in predicting protein-ligand structures and surpasses traditional methods in predicting binding affinity. Furthermore, IsoDDE can identify previously hidden binding pockets on proteins solely from their amino acid sequences, a capability that previously required extensive experimental work.

University of Arizona and Quantoom Biosciences collaborate on AI and mRNA cancer vaccine framework

Researchers at the University of Arizona are collaborating with Quantoom Biosciences to develop an AI and mRNA-based framework for personalized cancer vaccines. This platform will identify neoantigen candidates to train the immune system against mutated tumor proteins. Separately, Stanford Medicine has developed Nuclei.io, an AI tool that enhances the speed and accuracy of pathologists in identifying cells, which is crucial for clinical trial enrollment, particularly in cancer.

AI System Outperforms Radiologists in Pancreatic Cancer Detection on CT Scans

The PANORAMA study has shown that an AI system achieved a higher diagnostic performance than radiologists in detecting pancreatic cancer on CT scans, with an AUROC of 0.92 compared to the radiologists' pooled performance of 0.88. The AI detected 38% more cancers at matched specificity and reduced false positives by 26% at matched sensitivity, suggesting it can augment radiologist capabilities.

Evogene and QUT Partner to Develop AI-Driven Cancer Therapeutics

Evogene and Queensland University of Technology (QUT) have announced a collaboration to develop AI-driven small molecule cancer therapeutics. This partnership will focus on therapy-resistant non-small cell lung cancer (NSCLC) and other cancers, utilizing Evogene's ChemPass AI platform to generate and prioritize potential drug candidates.

Insilico Medicine Partners with MSK to Discover Gastroesophageal Cancer Targets

Insilico Medicine has partnered with Memorial Sloan Kettering Cancer Center (MSK) to discover novel therapeutic targets for gastroesophageal cancers. This collaboration will integrate MSK's clinical data with Insilico's AI-driven drug development platform to advance treatment strategies.

Bristol Myers Squibb adopts Evinova AI platform; Evogene and QUT collaborate on AI cancer therapeutics

Bristol Myers Squibb is implementing Evinova's AI-enabled clinical development platform globally to enhance trial design and accelerate timelines. Evogene and Queensland University of Technology (QUT) are collaborating to advance AI-driven cancer therapeutics, focusing on chemotherapy and targeted therapy-resistant non-small cell lung cancer.

Johns Hopkins and MIT researchers use AI to advance cancer drug discovery and protein manufacturing

Johns Hopkins Medicine researchers are employing AI to expedite and refine cancer drug discovery, aiming for a faster, more precise, and cost-effective process. Scientists have created an AI system that designs custom proteins to guide cancer-fighting immune cells more effectively. Additionally, MIT chemical engineers have developed a new AI model that optimizes protein manufacturing processes in industrial yeasts, potentially lowering the cost of protein drug development.

Thermo Fisher Scientific's PPD, Evogene, and Lantern Pharma advance AI in drug development

In AI drug development, Thermo Fisher Scientific's PPD has partnered with Datavant to enhance real-world data integration in clinical research. Evogene is expanding its alliance with Google Cloud to integrate AI agents. Additionally, Lantern Pharma showcased its ZETA AI platform, demonstrating its capability to design new cancer drugs by analyzing vast datasets.

Scientists Develop AI Blood Tests for Brain and Liver Cancer Detection

Scientists have developed a new AI-powered blood test capable of detecting brain cancer with approximately 75% accuracy by analyzing DNA and immune system signals. Additionally, an updated AI blood test, DELFI, can now detect liver cancer with over 80% accuracy, including in its early stages.

MIT Professor Regina Barzilay Develops AI Model MIRAI for Early Breast Cancer Prediction

Dr. Regina Barzilay, an MIT professor, has developed an AI model named MIRAI capable of predicting a patient's risk of developing breast cancer within five years. The model excels at identifying subtle changes in mammograms that are difficult for human eyes to discern, advancing early cancer detection capabilities.

Takeda Partners with Iambic Therapeutics for AI-Driven Drug Discovery

Takeda Pharmaceutical has entered into a significant partnership with Iambic Therapeutics, aiming to utilize artificial intelligence for drug discovery in cancer and other diseases. This collaboration grants Takeda access to Iambic's AI-driven platform and a predictive model for protein-receptor interactions. The deal has a potential value exceeding $1.7 billion.

Researchers develop AI models for cancer-linked protease sensors and automate rare cancer cell detection

Researchers have developed AI models for designing peptides that act as sensors for cancer-linked proteases, potentially enabling early detection anywhere in the body. Additionally, a new AI algorithm automates the detection of rare cancer cells in blood samples for liquid biopsies, significantly reducing analysis time. Johns Hopkins Medicine is also advancing cancer care with AI-based liquid biopsies showing promise for early detection of brain and liver cancers.

AI Improves Early Detection of Aggressive Cancers

New research indicates AI-assisted mammography can significantly improve the early detection of aggressive breast cancers, reducing interval and aggressive cancer rates. Additionally, AI-generated sensors using peptides are being developed for early cancer detection by signaling the presence of cancer-linked proteases. Advances in AI-based liquid biopsies and blood tests also show promise for detecting brain and liver cancers, respectively.

GV20 Therapeutics develops AI-discovered antibody drug GV20-0251 for advanced solid tumors

GV20 Therapeutics has utilized AI to discover and develop a new antibody drug, GV20-0251, which targets a novel immune checkpoint, IGSF8. This drug showed promising results in a phase one clinical trial for advanced solid tumors, helping to shrink tumors or stabilize disease progression.

New AI Model Outperforms Oncotype DX in Breast Cancer Recurrence Prediction

A new multimodal artificial intelligence model has demonstrated superior accuracy in predicting breast cancer recurrence compared to the Oncotype DX genomic test. This AI model integrates molecular, histopathologic, and clinical data from patients to provide more precise recurrence risk scores for HR-positive, HER2-negative breast cancer.

Generative AI Revolutionizes Drug Discovery and Cancer Detection

Generative AI is showing significant promise in revolutionizing drug discovery by accelerating timelines and reducing failure rates, particularly in designing antibody candidates for previously undruggable targets. Additionally, researchers are utilizing AI to design molecular sensors for early cancer detection, aiming to identify the disease in its initial stages.

Mass General Brigham Investigators Develop BrainIAC AI Model for Brain MRI Analysis

Investigators from Mass General Brigham have developed a new AI foundation model named BrainIAC. This tool can extract multiple disease risk signals from routine brain MRIs, enabling it to estimate brain age, predict dementia risk, detect brain tumor mutations, and forecast cancer survival rates.

AI-assisted mammograms improve early breast cancer detection in Swedish study

New research suggests that AI-assisted mammograms can enhance the early detection of breast cancers and decrease the occurrence of interval diagnoses. A study involving 100,000 women in Sweden found that AI-supported screening led to fewer aggressive or advanced cancers being diagnosed between screenings.

AI Algorithm Predicts Oropharyngeal Carcinoma Outcomes from CT Scans

An AI algorithm has demonstrated the ability to predict outcomes for oropharyngeal carcinoma by identifying extranodal extension (ENE) from CT scans. A study involving over 1,700 patients found that the number of ENE nodes detected by AI was significantly associated with overall survival and disease control. This application of AI offers a powerful biomarker for assessing patient prognosis.

AI improves breast cancer screening in Sweden, reduces interval cancers by 12%

A large trial in Sweden suggests AI can significantly improve breast cancer screening, leading to a 12% reduction in interval cancers and better detection of aggressive subtypes. Additionally, Norwegian hospitals are implementing AI diagnostic tools like PROVIZ for prostate cancer, enabling quicker and more accurate assessments.

ConcertAI Launches Accelerated Clinical Trials AI Platform at SCOPE 2026

ConcertAI has launched Accelerated Clinical Trials (ACT), an enterprise agentic AI platform aimed at automating and optimizing the entire clinical trial lifecycle. Unveiled at SCOPE 2026, ACT integrates real-world data with advanced AI workflows to potentially shorten trial timelines by 10 to 20 months and reduce costs.

BostonGene's AI for HER2 expression validated in independent study

BostonGene has announced a significant independent validation of its AI and machine learning capabilities for assessing HER2 expression in breast cancer. A blinded, multi-vendor HER2 benchmarking study showed high agreement rates for BostonGene's foundation model, as published in Modern Pathology.

FDA Grants Orphan Drug Designation for AI-Related Pancreatic Cancer Imaging Agent

The FDA granted several critical designations for novel cancer therapies, including an orphan drug designation for an AI-related imaging agent for pancreatic cancer, highlighting the ongoing shift towards precision medicine.

Asia Pacific AI Cancer Diagnostics Market Projected to Grow to $247.4 Million by 2030

The AI cancer diagnostics market in Asia Pacific is projected to grow from $41.7 million in 2023 to $247.4 million by 2030, with 80% of FDA-approved AI oncology devices focusing on diagnostics.

New AI Algorithm Detects Rare Cancer Cells, Improves Breast Cancer Screening

A new AI algorithm has been invented to automatically detect rare cancer cells in blood samples within approximately 10 minutes, a crucial step for liquid biopsies. Additionally, a large trial in Sweden found that using AI in breast cancer screening reduced the rate of later diagnosis by 12% and increased early detection rates.

Pharmaceutical Companies Leverage AI to Streamline Clinical Trials and Regulatory Submissions

Pharmaceutical companies are increasingly leveraging AI to streamline clinical trials and accelerate regulatory submissions, optimizing time-consuming processes in drug development. This application focuses on improving efficiency rather than new molecule discovery.

Researchers develop AI models for cancer detection and treatment, revolutionize clinical trials

Researchers have developed AI models to design peptides for sensors that detect cancer early and custom proteins to guide immune cells to target cancer cells more effectively. Additionally, AI is revolutionizing clinical trials by accelerating drug development, improving patient recruitment, and reducing trial failures through tools like causal inference and digital twins.

Researchers develop AI tools for early cancer detection and improve radiologists' accuracy

Researchers have developed AI-generated molecular sensors for early cancer detection via urine tests and an AI tool to automate cancer cell detection in blood samples. A study also found that AI significantly improves cancer detection rates for breast radiologists. These advancements aim to enhance early diagnosis and treatment of various cancers.

Jeeva Clinical Trials urges life sciences industry to modernize infrastructure for AI drug development

Researchers have developed AI-designed peptide sensors for early cancer detection via urine tests, and generative AI is now processing complex medical datasets significantly faster than human experts. Additionally, Jeeva Clinical Trials is urging the life sciences industry to modernize infrastructure to fully leverage AI in drug development, emphasizing the need for unified systems and regulatory compliance.

Researchers develop AI for cancer detection sensors; MIT engineers create AI for protein manufacturing

Researchers have developed an AI model to design peptide-based sensors for early cancer detection, potentially enabling at-home tests for various cancers. Separately, MIT chemical engineers created a new AI model that optimizes protein manufacturing processes, potentially reducing costs for cancer-treating drugs like monoclonal antibodies.

Researchers develop AI model to design cancer-detecting peptides

Researchers have created an AI model capable of designing peptides that can act as sensors for cancer-specific proteases. These peptides, when incorporated into nanoparticles, can detect the presence of these overactive enzymes throughout the body. This breakthrough holds promise for developing new methods for early cancer detection, potentially even for at-home use.

Scientists use AI to design cancer-targeting proteins and Russian researchers develop breast cancer detection AI

Scientists are using AI to design custom proteins that act as a 'GPS' for cancer-fighting immune cells, guiding them to target and destroy cancer cells. Russian researchers have also created a neural network capable of detecting early-stage breast cancer from CT scans in minutes, reducing clinical error probability by approximately 20%.

Scientists use AI to design custom proteins for cancer-fighting immune cells

Scientists are using AI to design custom proteins that act as a 'GPS' for cancer-fighting immune cells, guiding them to targets and killing melanoma cells in lab experiments. Stanford Medicine developed an AI tool, Nuclei.io, to enhance pathologists' efficiency and diagnostic accuracy by rapidly identifying specific cells in biopsy samples. A trial in Sweden showed AI can help doctors identify more breast cancer cases during routine screenings by analyzing mammograms.

Scientists use AI to design proteins guiding immune cells to kill cancer

Scientists have utilized AI tools, including generative AI model RFdiffusion, to design custom proteins that act as a "GPS" for cancer-fighting immune cells. These AI-designed proteins, when engineered onto T cells, have shown the ability to rapidly kill melanoma cells in lab experiments. This approach represents a new method for utilizing AI in cancer treatment.

Researchers develop AI models for early cancer detection, including endometrial cancer and rare cell identification

Researchers have developed an AI model to design peptide-based sensors for early cancer detection, potentially enabling at-home tests. Separately, a novel AI model named ECgMPL has demonstrated near 100% accuracy in identifying endometrial cancer and can be adapted for other cancer types. Additionally, a new AI algorithm called RED can automate the detection of rare cancer cells in blood samples within 10 minutes.

AI models ECgMPL and AQuA achieve high accuracy in cancer detection and image error identification

A new AI model, ECgMPL, has demonstrated 99.26% accuracy in identifying endometrial cancer from microscopic images, significantly surpassing human diagnostic capabilities. Additionally, an AI system named AQuA has been developed to detect errors in digital pathology images with 99.8% accuracy. AI-assisted mammography trials suggest a reduction in aggressive breast cancer detection rates.

New AI Tools Predict Cancer Recurrence, Detect Pancreatic Cancer Early, and Aid Research

A new AI test can predict breast cancer recurrence risk more quickly and affordably than genomic testing. Mayo Clinic developed an AI model that detects pancreatic cancer on CT scans up to three years earlier than standard diagnosis. Additionally, a bipartisan House bill, the 'AI for Kids With Cancer Act,' has been introduced to accelerate pediatric cancer research using AI.

AI in Pathology Market Projected to Reach $1.15 Billion by 2033; AI-Assisted Colonoscopies Improve Detection

The global AI in pathology market is projected to reach $1.15 billion by 2033, driven by precision medicine and digital healthcare. AI-assisted colonoscopies have shown improved detection of precancerous lesions, potentially preventing colorectal cancer. AI platforms are accelerating drug candidate discovery, with companies like Insilico Medicine significantly reducing timelines.

AI Prostate Test Integrated into Routine Clinical Practice in Puerto Rico

CorePlus has integrated the ArteraAI Prostate Test into its diagnostic workflow in Puerto Rico, marking the first time this AI test for prostate cancer biopsies has been used in routine clinical practice in the region. This test analyzes digital biopsy images to predict treatment response and long-term outcomes.

FDA Clears ArteraAI Breast Tool; New AI Models for Cancer Detection and Drug Discovery Emerge

The FDA has cleared ArteraAI Breast, an AI-based digital pathology tool for early-stage breast cancer risk stratification. Recursion announced progress in its AI-driven drug discovery platform. New AI tools, SPARK and STimage, have been developed for analyzing tissue sections and detecting hidden cancer markers, respectively. The REDMOD AI model continues to show potential in detecting pancreatic cancer up to three years before clinical diagnosis.

Roche establishes AI factory to accelerate drug development; Ibex launches new AI pathology platform

Roche is establishing a large-scale AI factory to accelerate drug development, with early results showing AI designing an oncology treatment molecule 25% faster. Ibex Medical Analytics has launched a new AI-powered pathology platform, Ibex 4, to assist with breast cancer biopsy analysis. Additionally, Spotlight Pathology secured £1.4 million to commercialize its AI tools for blood cancer diagnosis, and regulatory bodies like the EMA and FDA have published principles for the responsible use of AI in drug development.